Stockwinners Market Radar for December 05, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:50 EST Momentus provides update on SpaceX Transporter-9 mission - The company states: "Momentus announced an update on its latest mission that launched on the SpaceX Transporter-9 mission on November 11. On this mission, Momentus used a third-party deployer system to deliver payloads into orbit. Momentus supported five payloads for four customers. Since launch, the company has confirmed the deployment of the Hello Test 1 and 2 satellites for Hello Space. Momentus cannot confirm the deployment of the remaining three satellites for three other customers and based on the results of a detailed investigation undertaken, the company does not believe those satellites were released from the third-party deployer system."

20:11 EST Cathie Wood's ARK Investment bought 126K shares of Trade Desk today

20:05 EST Novartis gets FDA approval for Fabhalta in adults with PNH - The company states: "Novartis announced that the FDA approved Fabhalta as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria, or PNH. Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH]). In clinical trials, treatment with Fabhalta increased hemoglobin levels (greater than or equal to 2 g/dL from baseline in the absence of RBC transfusions) in the majority of patients and in APPLY-PNH nearly all patients treated with Fabhalta did not receive blood transfusions. The FDA approval is based on the Phase III APPLY-PNH trial in patients with residual anemia despite prior anti-C5 treatment who switched to Fabhalta, which demonstrated superiority in hemoglobin improvement in the absence of RBC transfusions and in transfusion avoidance rate over patients who stayed on anti-C5 treatments. Approval was also supported by the Phase III APPOINT-PNH study in complement inhibitor-naive patients."

19:53 EST Intapp CEO sells $3.2M in common stock - In a regulatory filing, Intapp disclosed that its CEO John Hall sold 85.6K shares of common stock on November 30th in a total transaction size of $3.2M.

19:35 EST GAP Airports reports November traffic up 0.4% from last year - Grupo Aeroportuario del Pacifico announces preliminary terminal passenger traffic figures for November 2023, compared with the same period of 2022. For November 2023, the total number of terminal passengers at GAP's 12 Mexican airports increased by 0.4%, compared to the same period in 2022. Los Cabos and Puerto Vallarta presented an increase in passenger traffic of 4.3% and 3.7%, respectively, compared to November 2022. On the other hand, Montego Bay presented an increase in passenger traffic of 7.3% compared to the same period of 2022.

19:00 EST Marcus & Millichap enters strategic partnership with EquityMultiple - Marcus & Millichap announced it has made an equity investment in EquityMultiple, a New York-based real estate financing and investment technology platform. The partnership will provide sponsors and operators supplemental private capital financing sources and give accredited investors streamlined access to unique real estate equity and credit opportunities. "Our investment in EquityMultiple allows MMI to be part of a leading innovative technology platform that further expands our array of capital sources and solutions and creates synergies to facilitate the acquisition, recapitalization and restructuring needs of any commercial real estate transaction," said J.D. Parker, Marcus & Millichap's chief operating officer, Eastern Division. "Our firm strategically invests in proptech ventures that we believe will help transform the industry and we are excited to join forces with the EquityMultiple team."

18:37 EST 5E Advanced Materials trading halted, news pending

18:02 EST Avis Budget declares special cash dividend of $10.00 per share - Avis Budget declared a special cash dividend of $10.00 per share of common stock. The special cash dividend is payable on December 21 to stockholders of record as of the close of business on December 15. In addition, the company has purchased approximately 1.3 million shares of its common stock to date in Q4 for an aggregate purchase price of approximately $240M. There is approximately $820M remaining under its share repurchase program and the company expects to continue retiring shares throughout the balance of 2023 and beyond.

17:44 EST IGM Biosciences advances over 1% after earlier reoganization statement - Shares are up 7c or 1.09% in after market trading to $6.50 per share, after indicating to investors earlier that a reduction in workforce of approximately 22% was in the works, resulting in an IGM extension of its cash runway into the second quarter of 2026.

17:32 EST Robinhood says crypto trading spiked 75% in November from previous month - In an earlier regulatory filing, financial services platform Robinhood Markets (HOOD) gave an investor update. The company said, in part: Ahead of management meetings with the investment community, Robinhood Markets provided early insight into certain November 2023 operating data and posted an investor presentation. In November 2023, customers contributed roughly $1.4B of Net Deposits to Robinhood. Additionally, November Equity Notional Trading Volumes and Options Contracts Traded were roughly in line with October 2023 levels, and November Crypto Notional Trading Volumes were roughly 75% above October 2023 levels. The Company plans to release its full November 2023 Operating Data in the coming weeks. Publicly traded companies in the crypto space include Bit Digital (BTBT), Coinbase (COIN), Core Scientific (CORZ), Greenidge Generation (GREE), Marathon Digital (MARA), MicroStrategy (MSTR), Riot Blockchain (RIOT) Grayscale Bitcoin Trust (GBTC), $BTC, and $ETH Reference Link

17:16 EST Pan American Silver provides annual exploration update - Pan American Silver "released new exploration drill results for its Jacobina, El Penon, La Colorada, Huaron and Timmins properties and for its La Colorada Skarn project. These drill results demonstrate continued potential for organic growth of mineral reserves and mineral resources in and around the Company's operations. Pan American's drill program in 2023 is focused on near-mine exploration and resource conversion throughout its portfolio of operating mines. A total of 373,780 metres has been drilled during the ten months ended October 31, 2023, out of a 450,000 metre drill program planned for 2023. The mineral reserves and mineral resources update as at June 30, 2023, which was released on August 24, 2023, reflects only a portion of the 2023 drill program. The Company plans to incorporate the results of the full 2023 drill program, including results for the Company's other assets not referenced in this news release, in a mineral reserve and mineral resource update as at June 30, 2024."

17:02 EST LGI Homes reports 522 November home closings - LGI Homes announced it closed 522 homes in November 2023, up from 412 homes closed in November 2022, representing year-over-year growth of 26.7%. As of November 30, 2023, the Company had 112 active selling communities.

17:00 EST Asana falls 8% to $21.35 after Q3 results and guidance

16:51 EST Check Point provided certain information to SEC related to SolarWinds hack - According to a regulatory filing, on December 5, 2023, Check Point Software Technologies announced that, in response to an inquiry from the Securities and Exchange Commission enforcement division, the Company voluntarily provided certain information and documents related to its experience three years ago with the 2020 SolarWinds Orion cyber vulnerability. The Company cooperated with the inquiry and advised the SEC on the Company's use of such software and the absence of any access to customer information, sensitive data, code or any other company asset. The Company identified access leading to a limited testing environment, which it believed was immaterial, and the Company is engaged in settlement discussions with the SEC as to whether this was to be disclosed in the Company's historical annual report. The Company believes that any payment to the SEC in connection with such settlement would not have a material impact on the Company's results, operations or financial condition. Further, the matter does not implicate any historical financial statements filed by the Company with the SEC. There is no assurance that the matter will eventually be settled under the terms currently being discussed or at all, and any settlement would be subject to approval by the SEC Commissioners.

16:37 EST Tian Ruixiang receives noncompliance notification from Nasdaq - Tian Ruixiang announced that it received a written notice from the Listing Qualifications Department of Nasdaq, indicating that the company is not in compliance with the minimum bid price requirement of $1.00 per share under the Nasdaq Listing Rules. Based on the closing bid price of the company's Class A ordinary shares for the last 30 consecutive business days from October 17 to November 29, the company no longer meets the minimum bid price requirement set forth in Listing Rule 5550(a)(2).

16:35 EST Midland States announces new $25M stock repurchase pact - Midland States Bancorp announced that its Board of Directors has approved a new stock repurchase program that authorizes the Company to repurchase up to $25M of its common stock. The new stock repurchase program will become effective on January 1 and expires on December 31, 2024. The Company's current stock repurchase program expires on December 31 and has approximately $7.2 M remaining under the authorization.

16:32 EST Cboe Global Markets reports November trading volume - Reference Link

16:31 EST Rio Tinto announces update on Simandou iron ore project - The company states: "Rio Tinto will provide an update today at its Investor Seminar on the world class Simandou iron ore project in Guinea, which is being progressed in partnership with CIOH, a Chinalco-led consortium, Winning Consortium Simandou, Baowu and the Republic of Guinea. Simandou is the world's largest untapped high-grade iron ore deposit. The Simfer joint venture's mine concession held an estimated Total Mineral Resource as at 31 December 2022 of 2.8 billion tonnes, of which Rio Tinto is today reporting the conversion of an estimated 1.5 billion tonnes to Ore Reserves that support a mine life of 26 years, with an average grade of 65.3% iron3 and low impurities. Rio Tinto is also reporting Mineral Resources exclusive of Ore Reserves of 1.4 billion tonnes at 66.1% Fe and low impurities. Rio Tinto estimates that its initial4 share of capital expenditure to develop the Simfer mine and the co-developed rail and port infrastructure project is approximately $6.2 billion. Rio Tinto Executive Committee lead for Guinea and Copper Chief Executive Bold Baatar said: "We are continuing to work closely with the Government of Guinea, Chinalco, Baowu and WCS towards full sanction of this world class project by all partners. In what will be the largest greenfield integrated mine and infrastructure investment in Africa, more than 600 kilometres of new multi-use rail together with port facilities will be co-developed by the Republic of Guinea, Simfer and WCS. This will allow the export of up to 120 million tonnes per year of mined iron ore by Simfer and WCS from their respective Simandou mining concessions6 in the southeast of the country.7 The co-developed infrastructure capacity and associated cost will be shared equally between Simfer, which will develop, own and operate a 60 million tonne per year8 mine in blocks 3 and 4 of the Simandou Project, and WCS, which is developing blocks 1 and 2. Under the co-development arrangement, Simfer and WCS will deliver separate infrastructure scopes to leverage expertise9. Simfer will construct the approximately 70 km Simfer spur rail line and a 60 million tonne per year transhipment vessel port, while WCS will construct the dual track approximately 536 km main rail line, the approximately 16km WCS spur rail line and a 60 million tonne per year barge wharf. Once complete, all co-developed infrastructure and rolling stock will be transferred to and operated by the Compagnie du Transguineen joint venture, in which Simfer and WCS each hold a 42.5% equity stake and the Guinean State a 15% equity stake10. First production from the Simfer mine is expected in 2025, ramping up over 30 months to an annualised capacity of 60 million tonnes per year. The mine will initially deliver a single fines product before transitioning to a dual fines product of blast furnace and direct reduction ready ore. Simfer's initial capital funding requirement for the Simandou project is estimated to be approximately $11.6 billion, of which Rio Tinto's share is approximately $6.2 billion."

16:30 EST Macy's names Tracy Preston chief legal officer - Macy's announced that Tracy Preston has been named chief legal officer and corporate secretary of Macy's, Inc., effective January 8, 2024, and will report to Tony Spring, president and CEO-elect, Macy's, Inc. As chief legal officer, Tracy will be responsible for a broad range of legal affairs, litigation and compliance for Macy's, Inc., including employment, real estate, credit, commercial and regulatory matters, enterprise security and internal audit. Additionally, Tracy will act as legal advisor to senior leadership and the board of directors in her role as corporate secretary. "Tracy is a trusted legal and compliance expert, and I'm delighted to welcome her to our leadership team. For the past three decades, she has counseled global apparel and retail companies on strategic, business, operational and tactical matters, ensuring her experience will be an asset. Importantly, she brings a track record of aligning legal and risk mitigation approaches with business objectives and brand missions," said Tony.

16:29 EST IGM Biosciences plans to file IND for IGM-2644 development in 2024 - As an expansion of its autoimmune efforts, the Company also announced that it plans to file an Investigational New Drug or IND application to begin the clinical development of IGM-2644, its CD38 x CD3 T cell engager antibody, for the treatment of autoimmune diseases. As part of its strategic refocus, the Company is halting all hematologic oncology clinical development as well as the clinical development of its targeted cytokine product candidate. The Company is prioritizing the clinical development of IGM-2644, a CD38 x CD3 T cell engager antibody, in the treatment of autoimmune diseases, and it plans to file an IND for these purposes in 2024.

16:26 EST Phreesia jumps 6% to $15.61 after Q3 results, raised FY EBITDA outlook

16:23 EST Phreesia raises FY24 adjusted EBITDA view to ($39M) from ($54M) to ($49M)

16:22 EST IGM Biosciences announces reduction in workforce of approximately 22% - "IGM continues to have a tremendous opportunity to transform a variety of disease areas using an entirely new class of antibody medicines," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "Although we are very encouraged by the clinical and preclinical data that we have generated for the programs we are halting, given the difficult conditions in the capital markets for our industry, we have decided to focus our capital resources on those opportunities that we believe have the most potential to produce significant near-term value. We are very sorry that some of our dedicated and talented employees will be leaving IGM as part of this strategic refocusing, and we wish to extend our sincere thanks and assistance to them in this difficult transition." As a result of these actions, IGM expects to extend its cash runway into the second quarter of 2026.

16:19 EST IGM Biosciences announces strategic pipeline prioritization and cash runway - IGM Biosciences announced that it will focus its resources in two strategic areas: treating colorectal cancer using IgM death receptor 5 DR5 agonist antibodies, and treating autoimmune diseases using IgM T cell engager antibodies. As an expansion of its autoimmune efforts, the Company also announced today that it plans to file an Investigational New Drug IND application to begin the clinical development of IGM-2644, its CD38 x CD3 T cell engager antibody, for the treatment of autoimmune diseases. As part of its strategic refocus, the Company is halting all hematologic oncology clinical development as well as the clinical development of its targeted cytokine product candidate. The Company will continue to focus on the development of oncology and immunology and inflammation product candidates under its collaboration with Sanofi. In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent. As a result of these actions, IGM expects to extend its cash runway into the second quarter of 2026. "IGM continues to have a tremendous opportunity to transform a variety of disease areas using an entirely new class of antibody medicines," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "Although we are very encouraged by the clinical and preclinical data that we have generated for the programs we are halting, given the difficult conditions in the capital markets for our industry, we have decided to focus our capital resources on those opportunities that we believe have the most potential to produce significant near-term value. We are very sorry that some of our dedicated and talented employees will be leaving IGM as part of this strategic refocusing, and we wish to extend our sincere thanks and assistance to them in this difficult transition."

16:14 EST MasterCard authorizes up to $11B stock buyback, raises quarterly dividend 16% - Mastercard Incorporated announced that its Board of Directors has declared a quarterly cash dividend of 66c per share, a 16% increase over the previous dividend of 57c per share. The cash dividend will be paid on February 9, 2024 to holders of record of its Class A common stock and Class B common stock as of January 9, 2024. The Board of Directors also approved a new share repurchase program, authorizing the company to repurchase up to $11B of its Class A common stock. The new share repurchase program will become effective at the completion of the company's previously announced $9B program in December 2022. As of December 1, 2023, the company had approximately $3.5B remaining under the current approved share repurchase program.

16:11 EST Altisource Asset Management announces resignation Danya Sawyer - Altisource Asset Management Corporation announced the resignation of Danya Sawyer, Chief Operating Officer of Alternative Lending Group, the Company's principal operating subsidiary. Ms. Sawyer, whose departure was effective December 1, 2023, also served as AAMC's interim Chief Executive Officer during the recent restructuring of the Company's loan business. "We appreciate Danya's excellent service and contributions to the Company," said Chairman of the Board Ricardo Byrd. "We wish her well in her future endeavors." A successor CEO is expected to be announced within 30 days.

16:09 EST Aclaris in alopecia patent license pact with Sun Pharma includes $15M upfront - Aclaris Therapeutics announced an exclusive patent license agreement with Sun Pharmaceutical Industries or Sun Pharma. Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata or AA or androgenetic alopecia AGA . The agreement includes an upfront payment of $15M, regulatory and commercial milestones, and royalties. Aclaris exclusively licenses the patents from a third party, and has separate contractual obligations under which it owes a portion of the consideration received from Sun Pharma. "We are pleased to announce this patent license agreement with Sun Pharma, which represents our second out-license for this patent portfolio," stated James Loerop, Chief Business Officer of Aclaris.

16:06 EST Sterling Infrastructure announces $200M share repurchase program - Sterling Infrastructure announced that its Board of Directors has authorized a program to repurchase shares of Sterling's outstanding common stock. Under the program, Sterling may repurchase up to $200M of its outstanding common stock over the next 24 months.

16:05 EST Radiant Logistics authorizes 5M share stock repurchase program - Radiant Logistics announced that its board of directors has authorized the repurchase of up to 5M shares of the company's common stock through December 31, 2025. As of December 1, 2023, the company had 46,906,586 shares outstanding.

16:04 EST Novavax's updated COVID-19 vaccine now authorized in Canada - Novavax announced that Health Canada has granted expanded authorization for Nuvaxovid XBB.1.5 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. The Public Health Agency of Canada's National Advisory Committee on Immunization recommended XBB COVID-19 vaccines that target more recent, immune-evasive variants of the virus. The expanded authorization was based on non-clinical data showing that Novavax's COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax's vaccine induced neutralizing antibody responses to subvariants BA.2.86, EG.5.1, FL.1.5.1 and XBB.1.16.6 as well as CD4+ polyfunctional cellular responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax's vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants. In clinical trials, the most common adverse reactions associated with the vaccine included headache, nausea or vomiting, muscle pain, joint pain, injection site tenderness, injection site pain, fatigue and malaise. Novavax's updated COVID-19 vaccine is also authorized in the U.S., the European Union and by the WHO, and is under review in other markets.

16:02 EST Check-Cap founder recommends voting against Keystone merger - Symetryx encourages fellow shareholders of Check-Cap to review the news release issued by Yoav Kimchy, the founder and former chief technology officer, and shareholder, of Check-Cap, who has stated in an open letter to his fellow shareholders that the value of the intellectual property of Check-Cap was, in essence, disregarded and assigned no monetary value when valuing the Keystone Dental transaction. The company said, "Further to its news release of November 28, Symetryx continues to urge its fellow Check-Cap shareholders to vote against the Keystone Dental and for the Symetryx slate of highly qualified and independent director nominees. Symetryx is pleased to see that other stakeholders agree that the transaction with Keystone Dental DOES NOT provide the maximum value for shareholders. We once again urge all shareholders to reject the Keystone transaction by voting AGAINST Proposal #1, the Keystone transaction, and to support the Symetryx Board nominees by voting FOR each. Only with a new, independent Board, do we believe, that we shareholders will have the best opportunity to realize the full value of our investment and not give it away to Keystone's investors."

16:00 EST Addex Therapeutics Ltd - ADR trading resumes

15:43 EST Canada money laundering watchdog FINTRAC fines Royal Bank of Canada C$7.5M - FINTRAC announced that it has imposed an administrative monetary penalty on the Royal Bank of Canada . Following a compliance examination in 2022, this bank was imposed an administrative monetary penalty of $7,475,000 on November 3 for non-compliance with Part 1 of the Proceeds of Crime or Money Laundering and Terrorist Financing Act and its associated Regulations. Royal Bank of Canada was found to have committed the following three administrative violations: Failure to submit suspicious transaction reports where there were reasonable grounds to suspect that transactions were related to a money laundering offence;Failure to provide information in the prescribed form and manner in suspicious transactions reports; and Failure to keep written policies and procedures up to date. This penalty was imposed for administrative violations committed by RBC under the Proceeds of Crime Money Laundering and Terrorist Financing Act and its associated Regulations, and not for criminal offences for money laundering or terrorist activity financing. Reference Link

15:38 EST Merck KGaA says relapsing multiple sclerosis trials didn't meet primary endpoint - Merck KGaA is investigating a highly selective oral and central nervous system penetrant Bruton's tyrosine kinase inhibitor, or BTKi, as a potential treatment for relapsing multiple sclerosis, or RMS, in two pivotal phase III clinical trials - evolutionRMS 1 and evolutionRMS 2, together the clinical trials. Both clinical trials, evaluating the efficacy and safety of evobrutinib compared to teriflunomide for up to 156 weeks, did not meet the primary endpoint of reducing annualized relapse rates, or ARR, in people with RMS, the company disclosed. Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world.

15:20 EST Allete up 7% after Reuters says company exploring possible sale

14:52 EST NN, Inc. Director Gautam buys 50K shares of company stock - NN Inc director Rajeev Gautam disclosed the purchase of 50,000 shares of company stock at $2.37 per share on November 30, for a total transaction amount of $118,650.

14:02 EST NXP Semiconductors CFO Betz sells over $900K in company shares - NXP Semiconductors' CFO William Betz disclosed the sale of 4,428 shares of company stock at $204 per share on December 1, for a total transaction amount of $903,312.

13:42 EST Arvinas, Pfizer report interim data from trial of vepdegestrant with palbociclib - Arvinas (ARVN) and Pfizer (PFE) announced clinical data for vepdegestrant in combination with palbociclib. Interim results from the Phase 1b combination cohort demonstrate "encouraging" clinical activity in heavily pre-treated patients with a median of four lines of therapy across disease settings with locally advanced or metastatic ER positive/human epidermal growth factor 2 negative breast cancer. These data will be presented in a spotlight presentation at the 2023 San Antonio Breast Cancer Symposium. Vepdegestrant is a PROTAC ER degrader designed to directly harness one of the cell's natural protein disposal processes to specifically target and degrade the estrogen receptor. Vepdegestrant is being co-developed by Arvinas and Pfizer and is currently being evaluated as a monotherapy in the second-line setting in the ongoing Phase 3 VERITAC-2 trial and in the first-line setting in combination with palbociclib in the ongoing study lead-in cohort of the Phase 3 VERITAC-3 trial. Pending additional data and agreement with regulatory authorities, Arvinas and Pfizer plan to broaden development of vepdegestrant to include new combinations with cyclin-dependent kinase inhibitors in both the first- and second-line settings. The companies plan to initiate a new second-line Phase 3 trial of vepdegestrant in combination with palbociclib and potentially other CDK4/6 inhibitors, and a new first-line Phase 3 trial of vepdegestrant plus Pfizer's novel CDK4 inhibitor. Vepdegestrant + Palbociclib Phase 1b Study In a spotlight presentation, interim data from the Phase 1b cohort of the first-in-human ARV-471-mBC-101 study evaluating vepdegestrant in combination with palbociclib assessed the safety, tolerability and anti-tumor activity of the combination among 46 patients with heavily pre-treated locally advanced or metastatic ER+/HER2- breast cancer. At the time of data cutoff, patients had received a median of four prior therapies across all lines; 87% were previously treated with a cyclin-dependent kinase 4 and 6 inhibitor; 80% were previously treated with fulvestrant; and 76% were previously treated with chemotherapy, including 46% in the metastatic setting. Patients were treated once daily with oral doses of vepdegestrant at 180 mg, the recommended Phase 3 dose of 200 mg, 400 mg or 500 mg, plus 125 mg of palbociclib given orally once daily for 21 days, followed by seven days off treatment in 28-day cycles. Vepdegestrant in combination with palbociclib demonstrated: A clinical benefit rate of 63%, or 29/46 patients; at the RP3D of 200 mg, the CBR was 67%, or 14/21 patients CBR in patients with mutant ESR1: 72%, or 21/29 patients; at the RP3D of 200 mg, the CBR was 79%, or 11/14 patients CBR in patients with wild-type ESR1: 53%, or 8/15 patients; at the RP3D of 200 mg, the CBR was 43%, or 3/7 patients An objective response rate in evaluable patients with measurable disease at baseline of 42%, or 13/31 patients; at the RP3D of 200 mg, the ORR was 53% ORR in patients with mutant ESR1: 47% or 8/17 patients ORR at the RP3D of 200 mg: 60% ORR in patients with wild-type ESR1: 42%, or 5/12 patients ORR at the RP3D of 200 mg: 40% Median progression free survival of 11.1 months; 22 of 46 patients across all doses had progression events by time of data cutoff PFS in patients with mutant ESR1: 11.0 months, 13 of 29 patients had progression events by data cutoff PFS in patients with wild-type ESR1: 11.1 months, 8 of 15 patients had progression events by data cutoff In an assay of circulating tumor DNA, patients with ESR1 mutations demonstrated a -96.8% mean decrease in ESR1 mutant allele fraction after 1 cycle of treatment. The safety profile of vepdegestrant plus palbociclib was manageable with palbociclib dose reductions and/or interruptions per protocol which are consistent with those described in the prescribing label. The primary toxicity associated with the vepdegestrant plus palbociclib combination was neutropenia. Grade 4 neutropenia occurred in 8 of 21 patients treated at the RP3D of vepdegestrant plus palbociclib 125 mg. Grade 3/4 neutropenia occurred in 89% of all patients. There was a higher occurrence of Grade 4 neutropenia, although discontinuation rates of palbociclib and rates of infection were in line with historical palbociclib data. No cases of febrile neutropenia were reported in any of the 46 patients treated with the combination. Three of 46 patients discontinued palbociclib due to neutropenia including one out of 21 treated with the RP3D of vepdegestrant plus palbociclib 125 mg. The majority of Grade 4 neutropenia events occurred in the first cycle of treatment and occurrences of Grade 3/4 neutropenia decreased with palbociclib dose reductions as described in the prescribing label. The safety profile was otherwise consistent with the profile of palbociclib and what has been observed in other clinical trials for vepdegestrant. An increase in palbociclib exposure was observed compared to historical pharmacokinetic data, with similar increases observed with vepdegestrant 200 mg and 500 mg QD.

13:08 EST Microsoft adjusts Cloud pricing to U.S. dollar levels - Microsoft said that as communicated in October 2022, it has established a "defined and transparent cadence" to its existing process of aligning Microsoft Cloud pricing globally to U.S. dollar levels. Today, Microsoft is adjusting prices for Microsoft cloud services to "global levels and prioritizing local pricing stability for on-premises," which starting February 1, 2024. Reference Link

12:57 EST JPMorgan CFO says seeing 'solid' loan growth

12:44 EST JPMorgan sees single digit growth in Q4 investment bank fees vs. Q3

12:30 EST Olema Oncology announces interim results from Phase 1b/2 study of palazestrant - Olema Pharmaceuticals announced interim results from an ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibitor ribociclib, a Poster Spotlight Session on interim Phase 2 clinical data of palazestrant in combination with palbociclib, and a trials-in-progress poster for the OPERA-01 monotherapy Phase 3 pivotal trial at the San Antonio Breast Cancer Symposium at the Henry B. Gonzalez Convention Center in San Antonio, Texas. This disclosure was originally planned for December 7, 2023. However, on December 5, 2023, the 2023 San Antonio Breast Cancer Symposium published the posters ahead of schedule. These full data are scheduled to be presented on December 7, 2023, and copy of the posters are available now on Olema's website under the Science section. Palazestrant Phase 1b/2 Study in Combination with Ribociclib: A poster titled "A Phase 1b/2 study of palazestrant in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced and/or metastatic breast cancer" will be presented at SABCS. A more recent data cut, as of November 1, 2023, highlights the following: Across 19 patients who had completed at least one cycle of treatment as of the data cutoff date, the combination of up to 120 mg of palazestrant with 600 mg of ribociclib daily was well tolerated, with no safety signals or enhancement of toxicity and an overall safety profile remains consistent with the expected safety profile of ribociclib plus an endocrine therapy. Palazestrant did not affect ribociclib drug exposure in patients, and ribociclib had no clinically meaningful effect on palazestrant drug exposure. There were no dose-limiting toxicities, the maximum tolerated dose was not reached, and the majority of treatment-emergent adverse events were grade 1 or 2, with no grade 4 events observed. Neutropenia was reversible in all patients, and the timing was generally consistent with ribociclib-related neutropenia. Findings from this study support the continued use of palazestrant at the recommended Phase 2 dose of 120 mg in combination with 600mg of ribociclib, and enrollment in the dose-expansion portion of the study is ongoing. Palazestrant Phase 1b/2 Study in Combination with Palbociclib: A poster titled "A Phase 1b/2 study of palazestrant, an oral complete estrogen receptor antagonist and selective ER degrader, with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients", will be presented in a Poster Spotlight Session by Prof. Arlene Chan, FRACP, MMed, Breast Cancer Research Centre-WA, Curtin University, Breast Clinical Trials Unit, Hollywood Private Hospital, Nedlands, Australia. The presentation will highlight that: Across 46 patients as of the cutoff date of September 15, 2023, the combination of palazestrant with palbociclib daily was well tolerated, with an overall safety profile consistent with the expected safety profile of palbociclib plus an endocrine therapy. There was no observed drug-drug interaction between palazestrant and palbociclib, and there was no induced metabolism or increase in exposure of either palbociclib or palazestrant when administered in combination. Most treatment-emergent adverse events were grade 1 or 2. Neutropenia incidence was similar to the PALOMA-3 study; it was reversible in all patients and the timing was generally consistent with the palbociclib-related neutropenia. Tumor responses and prolonged disease stabilization were observed in this patient group, including in those previously exposed to CDK4/6 inhibitors, in both ESR1 mutant and ESR1 wild-type tumors. Partial responses were observed in seven patients, with two confirmed partial responses and five unconfirmed partial responses. The clinical benefit rate was 46% in all patients and 60% in patients with an ESR1 mutation at baseline. In patients naive to prior CDK4/6 inhibitor treatment, the CBR was 71%. 53% of patients had any reduction in target lesion size. Twenty-two patients remain on treatment, and efficacy data are still maturing. Findings from this study are consistent with previously reported data and support the ongoing clinical development of palazestrant in combination with CDK4/6 inhibitors for the treatment of ER+/HER2- metastatic breast cancer.

12:28 EST Charter: November has been 'similarly soft' vs. October - Charter said that in October, it had seen "a little bit" of carryover churn, adding that November has been "similarly soft."

12:26 EST Charter CFO says could see 'negative' broadband net adds in Q4 - Comments taken from UBS Global TMT Conference. Shares of Charter are down 8% to $366.63 in afternoon trading.

12:11 EST Paccar declares $3.20 per share extra cash dividend - Paccar declared an extra cash dividend of $3.20 per share, payable on January 4, to stockholders of record at the close of business on December 15. The company said, "Paccar has generated excellent shareholder returns due to its industry-leading premium quality vehicles, strong growth in aftermarket parts and financial services, and innovative use of technology to enhance customers' operational performance...Paccar's excellent profits and strong cash flow have enabled the company to invest in industry-leading new DAF, Kenworth and Peterbilt trucks, fuel efficient diesel and electric powertrain technologies, connected vehicle services, and next-generation manufacturing and parts distribution capabilities."

12:00 EST Sonida Senior Living falls -11.6% - Sonida Senior Living is down -11.6%, or -$1.27 to $9.71.

12:00 EST Designer Brands falls -32.5% - Designer Brands is down -32.5%, or -$4.16 to $8.65.

12:00 EST Cano Health rises 12.2% - Cano Health is up 12.2%, or $1.01 to $9.28.

12:00 EST American Express sees 10%+ revenue growth in 2024, beyond as 'achievable' - American Express Chairman and CEO Steve Squeri, at the Goldman Sachs U.S. Financial Services Conference, said he believes the company's 10%+ aspirational revenue growth in 2024 and beyond is "achievable" in a steady state and high growth environment, adding that "if we miss on the 10%, it's a year-to-year kind of thing." He said 10% aspirational revenue growth is "absolutely the right growth for us."

11:51 EST Airbnb names Dave Stephenson Chief Business Officer, Ellie Mertz CFO - Airbnb announced three updates about the company's executive team: Catherine Powell has decided to transition to an advisor role and move on from Airbnb next year; Dave Stephenson, Airbnb's CFO since 2019, is stepping into a new role as the company's first Chief Business Officer; Ellie Mertz has been promoted to Chief Financial Officer. CEO Brian Chesky said in an email: "We're introducing the role of Chief Business Officer because we're about to embark on our next chapter as a company. Airbnb is at an inflection point. We spent 2023 perfecting our core service, and we're now ready to turn the corner." Reference Link

11:30 EST ADM makes series of investments to expand business in Brazil - ADM is making a series of investments to continue to expand its broad-based business in Brazil. ADM is investing to expand crush capacity at three oilseed processing facilities: Campo Grande; Porto Franco; Uberlandia. In total, the investments are expected to add approximately 400,000 metric tons per year to ADM's crush capacity in Brazil.

11:20 EST Pioneer Natural, Exxon receive FTC request for additional information on merger - In a regulatory filing, Pioneer Natural (PXD) announced that it and ExxonMobil (XOM) each received a request for additional information and documentary materials from the Federal Trade Commission in connection with the FTC's review of the Merger. The effect of a Second Request is to extend the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, until 30 days after each of Pioneer and ExxonMobil has substantially complied with the Second Request issued to it, unless that period is extended voluntarily by the parties or terminated sooner by the FTC. Completion of the Merger remains subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction or waiver of the other closing conditions specified in the Merger Agreement. "Pioneer and ExxonMobil continue to work constructively with the FTC in its review of the Merger and continue to expect that the Merger will be completed in the first half of 2024, subject to the fulfillment of the closing conditions, including receipt of required regulatory approvals and approval of Pioneer's stockholders."

11:13 EST Spire Global trading halted, volatility trading pause

11:05 EST Truist Financial CEO sees NII bottoming in 1H24 - Comments taken from the Goldman Sachs 2023 U.S. Financials Conference.

10:55 EST MetLife CFO says 'quality will win out in every class of real estate' - Asked during the Goldman Sachs Financial Service Conference about his view of the real estate markets and if there is anything the company can capitalize on within its asset manager or general account, MetLife CFO John Dennis McCallion replied in part: "I mean, higher rates certainly have been a headwind in terms of funding cost for borrowers. Office specifically has been a bit of a headwind just as a result of the evolution and how office is being used. Although we're seeing some kind of small positive signs of that starting to reverse a bit, that pendulum swung pretty hard as a result of the pandemic. And we're starting to see, and you can see it in the paper, firms start to revert back to some level of in office. And so that will be -- that's a positive trend for that. Look, I think capital is still scarce out there. Higher rates, as I said, kind of create a headwind. But that dislocation does create opportunities in other sectors within real estate... So these things go through cycles. It's how we invest in this space. We assume they will go through cycles, which is why our philosophy is the way it is. And you need to find -- needing to do so in a disciplined way so that when you get here, you can manage accordingly. Overall, we think quality will win out in every class of real estate."

10:32 EST IXHL Stock trading resumes

10:11 EST 10X Capital Venture Acquisition II Corp trading halted, volatility trading pause

10:05 EST Wolters Kluwer taskes over European Investment Law and Arbitration Review assets - Wolters Kluwer Legal & Regulatory U.S. announced that it has taken over the assets of the European Investment Law and Arbitration Review. By integrating this review on Kluwer Arbitration, in addition to offering it as a separate publication on Kluwer Law Online and in print, both arbitration professionals and academics have easy access to the valuable analysis contained in the journal.

10:03 EST Carnival, Neuron announce partnership to accelerate onboard connectivity - Neuron and Carnival Corporatio announced a partnership to accelerate onboard connectivity across Carnival Corporation's global fleet. The company is using Neuron's vendor-neutral connectivity management platform to further increase operational efficiencies and reliable internet access on its ships. With Neuron, Carnival Corporation ensures that its guests and team members can take advantage of the best available connectivity, regardless of service provider.

10:00 EST Sphere Entertainment falls -14.7% - Sphere Entertainment is down -14.7%, or -$4.94 to $28.68.

10:00 EST Hovnanian rises 5.3% - Hovnanian is up 5.3%, or $5.24 to $104.14.

10:00 EST Culp, Inc. rises 9.1% - Culp, Inc. is up 9.1%, or 45c to $5.41.

09:47 EST La Rosa Holdings, Final Offer partner for transparency in real estate deals - La Rosa Holdings and Final Offer announced a strategic partnership to provide La Rosa's agents with a more transparent offer and negotiation experience for their clients. The companies said, "Final Offer's streamlined process allows sellers to commit to a minimum price as well as terms of the sale upfront. Pre-approved buyers make binding offers online. If the Seller chooses to offer a "Final Offer" price and terms an interested buyer can hit the button at any time and immediately put the home under agreement."

09:47 EST Sphere Entertainment falls -15.4% - Sphere Entertainment is down -15.4%, or -$5.18 to $28.44.

09:47 EST Annovis Bio rises 5.5% - Annovis Bio is up 5.5%, or 54c to $10.39.

09:47 EST J.Jill rises 7.5% - J.Jill is up 7.5%, or $2.18 to $31.01.

09:41 EST XPO, Inc acquires 28 service centers of Yellow for $870M - XPO, at auctions held on November 28, said it was selected as the successful bidder for 28 service centers of Yellow Corporation located across the United States for an aggregate purchase price of $870M. The acquired assets include the assumption of three leases and the right to designate, in consultation with Yellow, additional contracts that are related exclusively to the Acquired Assets, for a period of 45 days following the consummation of the Yellow Asset Acquisition. The Yellow asset Acquisition is intended to be consummated pursuant to Section 363 of the bankruptcy code, and remains subject to various conditions, including, among others, the entry by the bankruptcy court of a sale order and the satisfaction of certain other closing conditions, XPO added. The acquisition is expected to be accretive to adjusted EBITDA and dilutive to adjusted diluted earnings from continuing operations per share in 2024. Starting in 2025, the Yellow asset acquisition is expected to be accretive to adjusted diluted earnings from continuing operations per share. In connection with the acquisition, XPO entered into a senior secured bridge term loan credit agreement pursuant to which the company may borrow up to an aggregate amount of $870M.

09:39 EST Bank of America CEO 'still feels good' about Q4 NII guidance - Speaking at the Goldman Sachs Financial Services Conference, Bank of America CEO Brian Moynihan stated, according to a transcript: "Well, if you think about the fourth quarter, we still feel good about the NII guidance, $14 billion, which was what we said. We feel good -- the big issue on expenses, the FDIC resolution came through. So that's $2.1 billion to $2.2 billion, slightly higher than the original estimates, but that's just due to the math of the calculation in our expense of 15.6. So that sort of brings the total expense base to 17.7 to 17.8 depending on where the FDIC settles in. So we hit to 15.6, we feel good about. When you think about things like the investment banking, the fee pool looks to be down 10% to 15%. And we'll be at about $1 billion in fees this quarter is our best estimate now, which puts us just down low single digits, which outperforms the industry. And we've been doing that. Frankly, we've been gaining share in that business and Matthew and the team -- Matthew Koder and the team have done a good job. On the markets and trading, now we're this late in the quarter, you can look at it and say, it looks like we'll be up low single digits year-over-year, which is good performance by Jim and team, probably the best fourth quarter we ever had. It still has a seasonality from third quarter, but they've done a good job. And I think the other thing that we're just trying to get people sort of on par with us is the -- these tax deals. So we have been a major financier of renewable energy. So 10, 15, some percentage of all the renewables sits on our balance sheet tax equity, and that's what we've been doing to drive that business. And so the benefits have been coming through a tax line all year, but what happens in the fourth quarter, you get a ramp up of the deals that closed because everybody rushed to get stuff closed by year-end. And that looks like it would be $1.2 billion to $1.3 billion of negative other income, which is like rise in other years, but it's a big change from the third quarter. I'm just trying to get people straight there. There's always confusion about it. So where are the tax benefits? The tax benefits, you take a more pro rata, and that comes in all at once just by when the deal is closed. So those are 4, 5 major things. And the company's around while everything else, those are pretty much in par with what we said."

09:30 EST Adit EdTech Acquisition Cor trading halted, volatility trading pause

09:25 EST Smith Micro in multi-year SafePath deal with Tier 1 MNO in Europe, no terms - Smith Micro Software announces that it has signed a multi-year agreement to provide its flagship SafePath Digital Family Lifestyle solution to a major Tier 1 mobile network operator, MNO in Europe. "Parents across Europe and around the world are grappling with the challenges of monitoring their children's location and safety, in both the physical and digital worlds, now more than ever," said Jonas Jacobsson, vice president sales EMEA for Smith Micro. "These issues are top of mind amongst parents, and offering this solution will enable the MNO to deliver a new level of value and trust to its subscribers."

09:18 EST Petros Pharmaceuticals partners with Idea Evolver - Petros Pharmaceuticals announces its partnership with Idea Evolver. The partnership will focus on developing an application to help facilitate the technology element for the Company's prescription to OTC switch for its erectile dysfunction drug STENDRA. The application will be developed using IE's proprietary Rx-to-OTC platform, CodeScripts.

09:17 EST Transcode Therapeutics to present Phase 0 data at 2023 San Antonio symposium - TransCode Therapeutics will present data from a Phase 0 clinical trial with its lead candidate, TTX-MC138, at this year's San Antonio Breast Cancer Symposium scheduled to take place December 5-9 in San Antonio, TX. The abstract, "Development of TTX-MC138, a First-In-Class miRNA-10b-Targeted Therapeutic Against Metastatic Cancers of Diverse Primary Disease Origins" will be presented as a poster. The poster will describe the clinical development of TTX-MC138, a therapeutic miR-10b inhibitor, delivered to metastatic tumor cells that has elicited complete responses and life-long disease remissions in preclinical models of adenocarcinoma. The poster details the IND-enabling work in support of the Phase 0 trial with Cu64-labeled TTX-MC138 as well as initial results from the trial. The trial involves injection of a microdose of Cu64-labeled TTX-MC138 into stage IV breast cancer patients, followed by positron emission tomography-magnetic resonance imaging. The trial seeks to determine the pharmacokinetics of TTX-MC138 and its uptake in metastatic lesions. Studies that will be presented in support of the Phase 0 trial include dosimetry/pharmacokinetic and tissue distribution, as well as metabolite analysis in non-human primates. In addition, initial clinical data on drug candidate PK and accumulation in clinical metastases, as well as drug candidate stability, will be discussed.

09:14 EST University of Manchester taps Matterport Digital Twins Platform - Matterport announced the University of Manchester implemented Matterport's Digital Twin Platform for the renowned Martin Harris Centre for Music and Drama to revolutionize the way students interact with the center, enhancing their understanding of the facilities on offer and improving their overall experience. Matterport's Digital Twin Platform, which includes solutions for Facilities Management, Property Marketing and Design and Construction Management, provided the students with a rich and immersive virtual environment, allowing them to explore and familiarize themselves with the MHC's buildings and facilities.

09:11 EST Intapp selected by McCabes Lawyers to strengthen client relationship management - Intapp announced that leading Australian law firm McCabes Lawyers has chosen to enhance its DealCloud platform with Intapp's relationship intelligence and email marketing capabilities. McCabes currently uses DealCloud to improve collaboration across practice groups, streamline complex processes, and centralize proprietary information. With DealCloud Dispatch, McCabes can better communicate with clients through firm newsletter and event invitation creation and management capabilities.

09:10 EST Fortinet extends SASE footprint through partnership with Digital Realty - Fortinet (FTNT) announced an expanded strategic partnership with Digital Realty (DLR), the largest global provider of cloud- and carrier-neutral data center, colocation, and interconnection solutions. This partnership accelerates the expansion of Fortinet Universal SASE, which has already surpassed over 100 locations worldwide. Leveraging PlatformDIGITAL, Digital Realty's global data center platform enables customers to secure their hybrid IT workflows across clouds and locations. "The expansion of our strategic partnership with Digital Realty will further propel Fortinet's global cloud network beyond the 100+ SASE locations available today and continue to accelerate customer adoption of our Universal SASE solution," said Michael Xie, Founder, President, and Chief Technology Officer of Fortinet. "Our customers now have even broader access to cloud-delivered security and connectivity for their distributed workforce, enabling them to seamlessly embrace the convergence of networking and security."

09:10 EST Procter & Gamble announces 'limited market portfolio restructuring' - In a regulatory filing, Procter & Gamble stated, "The Procter & Gamble Company announced today a limited market portfolio restructuring of its business operations, primarily in certain Enterprise Markets, including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. In connection with this announcement, the company expects to record incremental restructuring charges of $1.0 to 1.5 billion after tax, including foreign currency translation losses to be recognized upon the substantial liquidation of operations in the affected markets. The company estimates the large majority of these charges will be noncash. Although the timing of the completion of this restructuring program has yet to be determined, the company currently anticipates that these restructuring charges will be recognized in the fiscal years ending June 30, 2024 and 2025, with initial charges recognized in the quarter ending December 31, 2023. Combining the restructuring program with an impairment charge described further below, the company anticipates total charges of approximately $2.0 billion to $2.5 billion after tax over the periods described. The company estimates a large majority of these charges will be noncash. These charges will be reported as non-core charges."

09:09 EST Granite acquires suppliers LRC and MSG, financed through $150M loan and cash - Granite Construction announced the acquisition of Lehman-Roberts Company or or LRC and Memphis Stone & Gravel Company or MSG, longstanding asphalt paving and asphalt and aggregates producers and suppliers. This acquisition expands Granite's footprint and creates a new growth platform for Granite in the attractive Memphis metropolitan market. LRC operates seven strategically located asphalt plants serving the greater Memphis area and northern Mississippi. "With the completion of the acquisition, we are increasing our 2024 revenue target to a revenue range of $3.8B to $4B. While we expect the acquisition to be accretive to EBITDA, we are maintaining our 2024 adjusted EBITDA margin range of 9% to 11%." The acquisition was financed through a new term loan of $150M maturing on June 2, 2027, with the remainder funded through Granite's existing revolver and cash on hand. The Company does not provide a reconciliation of forward-looking adjusted EBITDA margin to the most directly comparable forward-looking GAAP measure of net income attributable to Granite Construction Incorporated because the Company cannot predict with a reasonable degree of certainty and without unreasonable efforts certain excluded items that are inherently uncertain and depend on various factors. For these reasons, we are unable to assess the probable significance of the unavailable information.

09:06 EST Nxu Inc. announces resignation of CFO Dwivedi, Wyant appointed interim CFO - Nxu announced that it has accepted the resignation of Apoorv Dwivedi, its Chief Financial Officer, CFO,who will be pursuing other opportunities. Nxu has appointed Sarah Wyant, its current Vice President of Finance, as Interim Chief Financial Officer. Dwivedi will continue to support the company in an advisory capacity as needed through the first quarter of 2024.

09:05 EST Dick's Sporting becomes official porting goods retailer of Notre Dame Athletics - Dick's Sporting Goods and Notre Dame Global Partnerships announced a multi-year, fully integrated partnership, with Dick's becoming the Official Sporting Goods Retailer of Notre Dame Athletics. Dick's Sporting Goods will have exposure and engagement with fans across Notre Dame Athletics' digital platforms, social media channels and national radio network. Fans will benefit from in-game giveaways and promotions, exclusive hospitality experiences, and sweepstakes. There will also be a variety of appearances from Notre Dame coaches, student-athletes, and cheerleaders at the Dick's store in the South Bend area,. Dick's and Notre Dame will also partner to support local youth sports activities.

09:04 EST NeuroMetrix announces publication of Phase 2 trial data on Quell - NeuroMetrix noted publication of results from a NIH-funded clinical trial of Quell titled "Wireless transcutaneous electric nerve stimulation for chronic chemotherapy-induced peripheral neuropathy: a proof-of-concept randomized clinical trial." The paper has been electronically published in The Journal of Pain. The study was a phase 2, multi-site, double blinded, randomized, sham-controlled trial. A total of 142 subjects with CIPN were randomized to an active or sham Quell device for 6-weeks. Subjects in both arms wore their device for 5 hours each day. Only a small number of minor adverse events were reported, primarily mild skin irritation that self-resolved. The trial met its pre-specified primary endpoint of a significant least-squares between-group difference of the EORTC-CIPN20 total score. The EORTC-CIPN20 is a validated patient questionnaire measuring CIPN related quality of life. Of greater clinical relevance, patients with moderate to severe CIPN symptoms of hot/burning pain, sharp/shooting pain or muscle cramping experienced about a 50% reduction in these symptoms for active treatment compared to about 30% for sham treatment. The study authors concluded "The study supports the preliminary efficacy of the TENS device for painful CIPN symptoms."

09:03 EST Duke Energy names Cameron McDonald Chief Human Resources Officer - Duke Energy announced that Cameron McDonald will become Senior Vice President and Chief Human Resources Officer, effective Jan. 1, 2024. She will succeed Ron Reising, who will retire at the end of the first quarter after an 18-year career with the organization and its predecessor companies. Reising has been with the company since 2004. Prior to leading Human Resources, he served as Ssenior VP of Operations Support. In her current role as Vice President of Talent Acquisition and Talent Management, McDonald is responsible for talent acquisition, leadership and employee development, succession planning and employee engagement. During her 22 years with the company, McDonald has held roles in human resources, including talent acquisition, talent management, diversity and inclusion, compensation, employee relations, and business partner consulting. McDonald also led a team focused on HR transformation, applying innovation and technology to reimagine HR products and services. Reising will remain in an advisory role throughout the transition.

09:02 EST Ibex partners with Sapling.ai for AI-powered messaging tools - ibex and Sapling.ai announced a new partnership to leverage Sapling's AI-powered messaging assistant technology as part of ibex's Wave X platform to empower agents to deliver an even greater customer experience, across diverse use cases. Sapling's language model-powered solutions generate relevant responses from a team response bank, provide deep learning-driven autocomplete suggestions across all messaging platforms, and offer a shared knowledge library for blazing fast search. These technologies provide real-time suggestions to help sales, support, and success teams compose more effective and personalized responses.

08:53 EST PureCycle Technologies resumes pellet production at Ironton facility - PureCycle Technologies has resumed pellet production at its flagship purification facility in Ironton, Ohio, following a scheduled pause to upgrade the plant. One of the most important improvements was the installation of an automatic screen changer on the final product extruder. The screen changer will help improve run times and enhance the production of PureCycle's PureFive Ultra-Pure Recycled resin. Over the Thanksgiving holiday, the Ironton maintenance outage was completed and the restart process was initiated. The restart process included time to unwind the maintenance activities, recharge the solvent and restart the plant. Feedstock was delivered on Sunday and pellet production resumed on Monday. The restart took a few days longer than expected, due predominantly to delayed electrical component deliveries.

08:52 EST LQR House unveils Bevage's direct-to-consumer ecommerce site - LQR House announcef the successful design, development, and launch of an innovative direct-to-consumer ecommerce site for Bevage. Timed perfectly for the holiday season when consumers traditionally indulge in wine and spirits as gifting items, the all-new website, https://www.bevage.com/, showcases a revamped look and enhanced functionality.

08:50 EST Roadzen announces its role as a founding member of the AI Alliance - Roadzen announced its role as a founding member of the AI Alliance, an international collaboration of over 50 leading organizations across industry, academia, and policy in advancing open, safe and responsible AI. The AI Alliance is committed to creating opportunities through a diverse range of institutions that can shape the evolution of AI in ways that better reflect the needs and complexity of our society. As a founding member, Roadzen is dedicated to building cutting-edge AI through fundamental and applied research, with a specialized focus at the intersection of mobility and insurance. Rohan Malhotra, Roadzen CEO: "The AI Alliance's focus on fostering an open and diverse ecosystem is a pivotal step in advancing AI research worldwide. It contrasts sharply with the idea of AI being tightly controlled by a few entities. As Roadzen joins this global initiative as a founding member, alongside the industry's leaders and researchers, our commitment is twofold: to support this vision and to leverage our expertise in building AI that is not just groundbreaking but also safe, accessible, and beneficial for all."

08:48 EST ParaZero, KULR Technology enter partnership to serve military, drone markets - ParaZero Technologies (PRZO) has formed a working partnership with KULR Technology Group (KULR) to leverage ParaZero's business network within the defense industry for applying KULR's vibration reduction technology on helicopter and rotorcraft fleets. By integrating the ParaZero SafeAir and SmartAir Trinity solutions with the KULR VIBE software in a combined product, the companies aim to achieve increased drone performance, operational efficiency, and improve safety to set a new standard for the industry.

08:47 EST Thumzup welcomes Joey Accardo Art to its cash rewards platform - Thumzup Media welcomes Joey Accardo Art located in Venice, CA, to its AdTech platform, where users are financially rewarded for promoting our advertising partners on social media. "We're thrilled to welcome Joey Accardo Art, led by Joseph Accardo, to the Thumzup platform," stated Robert Steele, Founder and Chief Executive Officer of Thumzup. "Thumzup's users are now able to earn cash while commissioning sports posters and prints from Joseph Accardo. Joey Accardo Art boasts of an impressive portfolio of replicas of Kobe Bryant, Tom Hardy, and Jerry Rice to name a few. Thumzup is excited to help keep spreading the word of Joseph Accardo's artistry so that it can be enjoyed by many more people."

08:46 EST Neogen announces biosecurity partnership with TerraNova - Neogen announced that it has partnered with the TerraNova Equestrian Center in Myakka City, Florida, making the company the official biosecurity provider of the facility. "In the wake of the COVID-19 pandemic, we have seen businesses of all kinds refocus on the necessity to take stronger precautions to stop the spread of disease," said Brittny Arbour, Senior Product Marketing Manager at Neogen. "Through our partnership with TerraNova, Neogen will be able to further showcase our biosecurity and equine health products, including the COMPANION line of cleaners and disinfectant solutions. We are proud to work with TerraNova to protect horses, their owners, and all others who visit the showgrounds."

08:44 EST Xometry updates process recommender to Instant Quoting Engine - Xometry announced an updated process recommender to its AI-powered Instant Quoting Engine, expanding coverage of manufacturing processes and improving accuracy. As CAD files are uploaded to the Xometry marketplace, the new process recommender instantly analyzes the geometric features of the file, identifies the most appropriate manufacturing process for the customer, and configures their quote. The new recommender is also trained to assess a customer's specific quote and order history, ensuring the best match for the buyer.

08:43 EST Presto Automation escalates activities to collect up to $11.1M from ruling - Presto Automation is escalating its activities to act on a previously reported avorable arbitration ruling from the Singapore International Arbitration Center related to a matter with its third-party subcontractor, XAC Taiwan, with respect to the legacy tablets used in its Touch business. Pursuant to the ruling, Presto was awarded approximately $11.1 million in damages. This arbitration ruling was affirmed on March 28, 2023 by the High Court in Singapore. The vendor appealed the ruling to the Singapore Court of Appeal, which is now scheduled to be heard in January 2024. This decision will be the vendor's last chance to attempt to set aside the arbitration ruling. In conjunction, Presto is actively involved in local court procedures in Taiwan, a "domestication" process that is required in the vendor's home jurisdiction to enforce the international damages award. This process may take another 12 to 18 months to domesticate the arbitration ruling in Taiwan. The vendor has limited defenses to such domestication and enforcement, provided that Singapore Court of Appeal rules against it.

08:42 EST Bigg Digital Assets' Netcoins provides update on November trading volumes - BIGG Digital Assets provides an update on the momentum in the crypto market and crypto trading results from Netcoins in November 2023. During the month of November it was clear that there is a change in market sentiment as investors have been allocating more capital into cryptocurrencies and crypto stocks. Crypto trading kicked off with significant uplift in December as Bitcoin hit an 18 month high of $42,000, now up 150% on the year. Inflows to the crypto market have increased significantly, mirroring volumes last seen during the October 2021 bullrun. Netcoins trading volumes and revenues have been hand in hand with this positive market movement and sentiment. Netcoins overall trading volume was up significantly in November, up nearly 93% Month over Month with over CAD$43M worth of crypto traded through the platform in November. Customer deposits rose 40% month over month as crypto investors look to get engaged with trading in the market. Netcoins saw its overall trading volume rise 27% from the prior month, a sign that the market volatility was triggering trading action on the platform. During the month of November, Netcoins saw over $17.2M traded through its OTC Desk. Netcoins OTC Trading desk is focused on servicing high net worth individuals, corporates, institutions and family offices to ensure we meet their bespoke trading needs. The OTC desk also has the unique opportunity to work with clients across North America through Netcoins and Netcoins USA.

08:40 EST Safety Shot files lawsuit against Capybara Research, adds Benzinga to suit - Safety Shot is providing a litigation update to the market regarding its newly filed lawsuit against Capybara research. Yhe company said, "On December 4th 2023, we filed a federal lawsuit in the United States District Court for the Southern District of New York against Capybara Research, a firm recently created and that enjoyed anonymity through various social media postings without any trail as to ownership while antagonizing our retail investment community by posting lewd and unprofessional graphics, intended to further embarrass the Company. Today, after weeks of investigatory work by our counsel, as well as the cooperation of third parties, we wish to announce that our attorneys have been successful in identifying the person responsible for the malicious article and is now taking all steps necessary to add to the lawsuit the name of the individual, as well as his address, and to serve that individual. Today we also announced that we also adding to our federal lawsuit the social media news outlet Benzinga for republishing, and continuing to republish the Capybara research and other false reports that continue to harm our retail investment community. We have also asked our new counsel to review all prior fundings the Company has done in order to determine whether they were done appropriately or if our rights have been violated. The Company had previously announced that it retained known dilution funder combatant Mark R. Basile, Esq, and his Securities and RICO litigation firm, The Basile Law Firm P.C. to assist the Company in investigating and prosecuting all claims in defense of the Company and its retail investors."

08:38 EST Gamer Pakistan announces partnership with Bramerz - Gamer Pakistan announced it has engaged Bramerz, a leading specialist digital marketing agency in Pakistan, to build and manage a comprehensive brand marketing and awareness campaign. Under the engagement, Bramerz and Khushnood will work to build public relations and marketing outreach in Pakistan and expand the social media and digital footprint of Gamer Pakistan. Bramerz will set the stage for a high-growth, high-revenue, localized business by introducing Gamer Pakistan to gaming influencers in the market, generating and progress relationships with brands and agencies in Pakistan, and facilitating meetings with Pakistani public institutions and officials. Khushnood will act as the Company's "Brand Evangelist" and official spokesperson in Pakistan. "We are thrilled to join forces with Badar and the Bramerz team, introduced to us by our advisor Rishy Jaitly, and incorporate their decades of digital marketing experience and success to broaden our outreach," said Jim Knopf, Chief Executive Officer of Gamer Pakistan. "Our success lies in understanding the local market like none other, and Badar and Bramerz bring vast local experience and unparalleled local knowledge to the table. We believe this synergy will significantly increase our brand equity in the market and the region, and position Gamer Pakistan to be the #1 Esports brand in the country with an active community participation."

08:37 EST Turbo Energy selects IBN to assist with communication initiatives - Turbo Energy has selected IBN to assist with its corporate communications initiatives. As part of the Client Partner relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Turbo Energy.

08:35 EST Inozyme reports inducement grants under Nasdaq listing rule - Inozyme Pharma announced that it granted stock options to a new employee to purchase shares of the Company's common stock, pursuant to the Company's 2023 Inducement Stock Incentive Plan, as inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Company's compensation committee granted nonstatutory stock options to purchase up to an aggregate of 65,000 shares of the Company's common stock to one new employee on December 1, 2023, at an exercise price of $3.85 per share, the closing price per share of the Company's common stock as reported by Nasdaq on December 1, 2023. The options have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee's start date and 2.0833% of the shares underlying the option vesting monthly thereafter, subject to such employee's continued service to the Company through the applicable vesting dates.

08:35 EST Hoth Therapeutics completes manufacturing of cancer fighting kit for IND - Hoth Therapeutics has completed the manufacturing of its drug substance HT-KIT using good laboratory practice. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and already has Orphan Drug Designation from the FDA. Hoth also recently completed its Pre-IND meeting with FDA in November. Hoth has now successfully completed manufacturing of the HT-KIT drug substance in collaboration with WuXi STA Pharmaceutical. Hoth plans to use the GLP drug substance in its upcoming pre-clinical studies required for its investigational new drug - IND - submission.

08:34 EST Sovos Brands appoints E. Yuri Hermida to president - Sovos Brands (SOVO) announced the promotion of E. Yuri Hermida to President of Sovos Brands, effective December 11, 2023. Mr. Hermida will continue to report to Todd Lachman, Founder and CEO of Sovos Brands. Hermida has served as Chief Growth Officer at Sovos Brands since October 2022. The Company continues to expect the pending merger with Campbell Soup Company (CPB) to be completed in 2024 and will continue to engage with the FTC on its review with the objective of closing in mid-2024.

08:33 EST Chubb, NetSPI launch cyber protection partnership - Chubb has announced an innovative collaboration with NetSPI to strengthen clients' cyber-risk profile via enhanced attack surface management and penetration testing solutions. Chubb policyholders in the U.S. and Canada can take advantage of NetSPI's full portfolio of proactive security solutions, including Breach and Attack Simulation, Attack Surface Management, as well as a suite of comprehensive penetration testing offerings, at preferred pricing, subject to applicable insurance laws. NetSPI's suite of solutions can be tailored to support any size business across all industries.

08:32 EST P&O Ferries adopts Intelligent Bio's Fingerprinting Drug Screening System - Intelligent Bio Solutions announced that leading pan-European ferry and logistics company, P&O Ferries, is now using the revolutionary portable Intelligent Fingerprinting Drug Screening System to support its drug and alcohol testing policy.

08:25 EST Amdocs' Vubiquity chosen by A+E Networks - Amdocs announced that Amdocs' Vubiquity has been chosen by A+E Networks to manage their VOD Transport & Content Distribution Services. This collaboration is set to expand the availability of A+E Networks' content, opening new monetization opportunities for Subscription Video on Demand and Ad-Supported Video on Demand.

08:23 EST NeoGenomics to present new data on RaDaR assay at SABCS - NeoGenomics announced new data highlighting its RaDaR assay for minimal residual disease will be presented at the 46th annual San Antonio Breast Cancer Symposium. RaDaR data will be presented during a Poster Spotlight Session featuring an updated analysis of the TRACER study, which assessed patients with early-stage breast cancer across multiple subtypes and the potential utility of using RaDaR in this setting, including for baseline detection, for monitoring therapy response in the neoadjuvant setting, and for post-operative recurrence monitoring. "The TRACER data continues to demonstrate the value of RaDaR technology, especially in excellent baseline detection of circulating tumor DNA to facilitate therapy response monitoring before and during neoadjuvant therapy," said Vishal Sikri, President of Advanced Diagnostics at NeoGenomics. "Evaluating therapy response is essential to cancer care, enabling patients and their physicians to make more informed treatment decisions that may improve cancer outcomes."

08:20 EST Credit Acceptance announces $500M senior notes offering - Credit Acceptance Corporation plans to offer $500.0 million aggregate principal amount of senior notes due 2028. We intend to use the net proceeds from the offering of the notes to fund our concurrent cash tender offer for any and all of our $400.0 million outstanding 5.125% senior notes due 2024, the redemption, in accordance with the terms of the indenture governing the 2024 notes, of any of the 2024 notes that remain outstanding after completion of the tender offer, and the payment of fees and expenses in connection with the foregoing and for general corporate purposes. Pending this application of the net proceeds from the offering of the notes, the net proceeds may be invested in short-term investments or applied to repay borrowings under our revolving credit facility without reducing the lenders' commitments thereunder.

08:19 EST Cazoo announces reverse stock split and increase in authorized share capital - Cazoo Group announced that its Board of Directors has approved a consolidation of the Company's issued and unissued share capital, par value 0.20c, at a ratio of 1-for-100 , as well as an increase in share capital . After giving effect to the reverse stock split and the share increase the Company's authorized share capital will be $22,105,000, divided into 100,000,000 Class A ordinary shares with a par value of 20c each , 25,000 Class B ordinary shares with a par value of US$0.20 each, 500,000 Class C ordinary shares with a par value of 20c each and 100,000,000 preference shares with a par value of 20c each. The reverse stock split and share increase will be effective at 4:05 p.m on December 5 and the Class A Shares will begin trading on a split-adjusted basis when the New York Stock Exchange opens for trading on Wednesday, December 6. The Class A Shares will continue to trade on the NYSE under the trading symbol "CZOO", but will trade under the following new CUSIP number starting December 6 G2007L 121. The reverse stock split and the share increase were approved by Cazoo's shareholders at the extraordinary general meeting of shareholders held on November 21, 2023 with over 97% approval.

08:19 EST Wells Fargo CEO sees some credit card growth continuing

08:18 EST Credit Acceptance announces tender offer for senior notes due 2024 - Credit Acceptance Corporation has commenced a cash tender offer for any and all of the $400,000,000 aggregate principal amount of its 5.125% Senior Notes due 2024 with CUSIP number 225310AN1. The Offer will expire at 5:00 p.m., New York City time, on December 14, 2023, unless extended. Holders who validly tender their Notes at or before the Expiration Time will receive $1,000 for each $1,000 principal amount of Notes accepted for purchase. Accrued and unpaid interest up to, but not including, the payment date, which is expected to be December 19, 2023, will be paid in cash on all validly tendered Notes accepted by us for purchase in the Offer. The complete terms and conditions of the Offer are set forth in the Offer to Purchase, including the related Notice of Guaranteed Delivery, dated December 5, 2023, and in the related Letter of Transmittal, along with any amendments and supplements thereto, which holders are urged to read carefully before making any decision with respect to the Offer.

08:17 EST Red Cat debuts in Latin America, continues global expansion efforts - Red Cat announces its debut into the Latin America defense and security market, a continuation of its global expansion efforts among U.S. allies. The Company will be showcasing its Teal 2 drone at Expodefensa 2023, a leading defense and security event being held in Bogota, Colombia on December 5-7, 2023. Red Cat will be exhibiting in booth D258 in the USA Partnership Pavilion. "Latin America has unique security and defense needs, and we believe that our Teal 2 product line is an ideal solution for governments and private enterprise alike given its wide array of features and affordable price," stated Jeff Thompson, Red Cat's Founder and CEO. "Our U.S. government certifications are a key feature to customers worldwide, as they underscore the effectiveness, ease of use, and security features that set our drones apart. We look forward to attending Expodefensa and to bringing our offering to the region, where it can be used to support border security, police and public safety, and Latin American military forces, among others."

08:16 EST Landstar System board declares special dividend of $2.00 per share - The Company announced that its Board has declared a special one-time cash dividend in the amount of $2.00 per share, payable on January 19, 2024, to stockholders of record as of the close of business on January 3, 2024.

08:15 EST Intra-Cellular highlights data presentations at ACNP annual meeting - Intra-Cellular Therapies announced data presentations at the American College of Neuropsychopharmacology, ACNP, 62nd Annual Meeting. Poster M91: "Lumateperone in the Treatment of Patients With Major Depressive Disorder and Bipolar Disorder with Anxious Distress and Mixed Features." The poster presented at ACNP reports on an important post-hoc analysis from Study 403 evaluating the antidepressant effects of lumateperone in a pre-specified subgroup of patients with mixed features exhibiting anxious distress. Lumateperone improved change from baseline for MADRS total score at Day 43 compared with placebo in all three populations with anxious distress: combined major depressive disorder/bipolar depression population, MDD individual population, and bipolar depression individual population. Greater improvements vs placebo in MADRS Total score occurred by Day 15 and persisted throughout the study. Similarly, in the Clinical Global Impression Scale-Severity lumateperone was superior versus placebo in all three patient populations. Cohen-D effect sizes on the CGI-s ranged from 0.48 to 0.66. The data presented in this poster represent further analyses from Study 403. Study 403 evaluated lumateperone 42mg as monotherapy in the treatment of major depressive episodes in patients with MDD with mixed features and in patients with bipolar depression with mixed features. Topline results for Study 403 are shown in Poster M88 and described below. Poster M131: "Discovery and Characterization of ITI-1549, a Novel Non-hallucinogenic Psychedelic For the Treatment of Neuropsychiatric Disorders." The company is developing novel non-hallucinogenic psychedelics that allow exploration of this psychoactive drug class in neuropsychiatric conditions including mood disorders without the liabilities of known psychedelics, such as induction of hallucinations and risks for cardiac valvular pathologies. The lead molecule in this program, ITI-1549, is advancing through IND enabling studies and is expected to enter human testing in late 2024 or early 2025. This poster describes the in-vitro and in-vivo preclinical characterization of ITI-1549. In vitro, similar to known hallucinogenic psychedelics, ITI-1549 exhibits high affinity binding to 5-HT2a receptors. Functionally, ITI-1549 acts as an agonist at 5-HT2A receptors favoring postsynaptic signaling within the beta-arrestin pathway over G-protein coupled pathways. In conclusion, ITI-1549 may be a safe, non-hallucinogenic psychedelic without the liability to induce hallucinations and cardiac pathologies while retaining the potential as an acute or chronic treatment of mood, anxiety and other neuropsychiatric disorders. Poster M88: "Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder." This poster describes further data analyses from Study 403 in mixed features. In this study, lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the MADRS for the combined mixed features patient population of MDD and bipolar depression and the individual patient populations of MDD with mixed features and bipolar depression with mixed features. Lumateperone 42mg also met the key secondary endpoint by demonstrating a statistically significant and clinically meaningful reduction in the Clinician's Global Impression scale or CGI compared to placebo at Week 6 in all three patient populations. Lumateperone was generally safe and well tolerated, with a side effect profile consistent with prior lumateperone trials. The most common adverse events in the study were somnolence, dizziness and nausea.

08:13 EST Wells Fargo CEO: Asset cap not a 'material limitation' today

08:13 EST Wells Fargo CEO says returns 'still not what they should be'

08:12 EST Cheer Holding unveils AI-powered metaverse retail strategy - Cheer Holding announced a groundbreaking advancement in its metaverse retail strategy. By harnessing state-of-the-art technologies, including artificial intelligence, digital twin, cloud computing, and blockchain, the Company is poised to deliver tangible outcomes and redefine the future of shopping in convergence of Web 3.0 and AI. The company said, "CHEERS Metaverse is a revolutionary platform meticulously crafted to provide an unparalleled immersive digital experience. Within this virtual realm, users effortlessly navigate through a dynamic landscape integrating intelligent retail, video on demand, social networking, and gaming. By seamlessly blending the physical and virtual domains, this visionary platform empowers users with real-time interactive experiences."

08:12 EST ABM initiates EPC program for Orange County Public Schools in Virginia - ABM announced the initiation of an Energy Performance Contracting program for Orange County Public Schools in central Virginia. This marks the third energy savings project for OCPS by ABM. The new project creates an additional $6.7 million in projected energy and operating cost savings over a twenty-year period. In addition, OCPS will undergo an extensive upgrade to a critical HVAC mechanical system, and LED lighting upgrades enhancing learning environments for all its schools.

08:10 EST CVS Health sees long-term adjusted EPS growth floor of 6% - Sees growth increasing over time. Opportunities to outperform, including Medicare Advantage margin improvement, are projected to add 3%-4% to adjusted EPS in 2025, CVS said in Investor Day presentation slides.

08:09 EST Genasys selected by Middle Eastern defense force to improve maritime safety - Genasys announced a new foreign military sales contract award for a Middle Eastern defense force. The multi-phase program, worth more than two million USD, will deploy Genasys' long-range acoustic hailing devices, LRADs, on multiple ships and shore installations across the country's Navy. Remotely controlled 950NXT for large vessels and various manually operated AHDs such as the 1000Xi and 450XL will provide long range, clear voice communications at thousands of meters out. "Our long-standing association with the U.S. military and our leadership in the acoustic hailing market, means Genasys is ideally placed to continue supporting international defense forces worldwide, and we continue to see an increase in demand from the international market", said Richard Danforth, Chief Executive Officer of Genasys.

08:08 EST Aquestive doses first patient in Phase 3 trial of Anaphylm Sublingual Film - Aquestive Therapeutics announced that the first patient has been dosed in its initial Phase 3 pivotal Pharmacokinetic clinical study of Anaphylm Sublingual Film. Anaphylm is the Company's orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis. "With the dosing of our first patient, we are officially one step closer to reaching our goal of filing our Anaphylm New Drug Application with the FDA in 2024," said Daniel Barber, Chief Executive Officer of Aquestive. "Anaphylm continues to be the first and only non-invasive, orally delivered epinephrine product candidate to demonstrate clinical results comparable to autoinjectors for the emergency treatment of severe allergic reactions, including anaphylaxis. We remain focused on continuing to demonstrate the PK comparability of Anaphylm to existing autoinjectors. We remain excited to address the significant unmet need for an orally delivered, convenient and effective product candidate."

08:08 EST Accenture and Unilever team on next generation AI - Accenture (ACN) is joining forces with Unilever (UL) s part of a strategic initiative to leverage Unilever's AI research and implementation of technologies that enhance productivity, drive efficiencies, and accelerate disruptive and AI-powered innovations at scale. The work will kick-off from Unilever's global AI Lab "Horizon3 Labs," recently opened in Toronto-a city recognized for its concentration of AI expertise and home to one of Accenture's six Gen AI studios in North America. The two companies will explore new applications to scale generative AI; for example, assets from Accenture's AI Navigator or its proprietary "switchboard," which allows a user to select a combination of models to address the unique business context. "This collaboration builds on our relationship of more than three decades with Unilever, which continues to raise the bar as a digital powerhouse and industry leader," said Julie Sweet, chair and CEO, Accenture. "The combination of Horizon3 Labs' disruptive innovation with Accenture's deep expertise and strong ecosystem partnerships will help Unilever scale AI and generative AI more rapidly and responsibly across its business and discover new pathways to value."

08:07 EST Penn Entertainment enters sports wagering partnership in North Carolina - Penn Entertainment announced that its wholly-owned subsidiary Penn Sports Interactive has entered into a long-term, multi-faceted partnership with Quail Hollow Club and the Wells Fargo Championship ahead of the launch of regulated online sports wagering in North Carolina. Under the agreement with Quail Hollow Club, Penn secures market access for its online sports wagering platform ESPN BET in North Carolina, subject to regulatory approvals. Additionally, ESPN Bet will become the exclusive official betting operator of the Wells Fargo Championship, a PGA Tour Signature Event held at Quail Hollow Club in Charlotte. As the event's official betting operator, ESPN Bet gains access to various marketing integrations, including the opportunity to activate and engage golf fans on-site during the tournament.

08:07 EST BioAtla presented Phase 2 trial data at IASLC 2023 on lung cancer - BioAtla presented a poster and discussion entitled "Phase 2 Trial of Mecbotamab Vedotin, BA3011, a CAB-AXL-ADC, Alone or in Combination with Nivolumab in Patients with Non-Squamous NSCLC" at the IASLC Conference December 1-3 and at a virtual KOL Event held December 4, 2023. "The results from the Phase 2 trial in NSCLC continue to show the potential of BA3011 in refractory NSCLC," said Jay Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. "Our recent regulatory feedback as well as the benefit-risk profile we have observed to date with our 1.8 mg/kg Q2W BA3011 dosing regimen support advancing this dose in a potentially registrational study. Furthermore, the meaningful antitumor activity among patients with AXL expression of only 1% supports the development of BA3011 in target agnostic populations. Taken together, we believe BioAtla has a significant commercial opportunity to access a larger market and treat more patients with our CAB-AXL-ADC asset." Data highlights from the poster presentation and KOL event include: In the BA3011 monotherapy arm, 1.8 mg/kg BA3011 Q2W showed encouraging efficacy signals: AXL-positive patients were enrolled and had received a median of at least 3 prior lines of therapy; Patients who previously experienced PD-1/L1 treatment failure were evaluable for efficacy at 12 weeks; objective response rate was 27.8% and disease control rate was 55.6%; Five of 15 evaluable patients with EGFR wild-type NSCLC who previously experienced PD-1/L1 treatment failure responded to BA3011 monotherapy; among these five responders, two patients with AXL TmPS of 1% experienced a PR; Median duration of response was estimated to be 4.8 months; Overall, treatment with BA3011 was well-tolerated with a manageable safety profile; The most frequent treatment-emergent AEs of any grade observed were fatigue, diarrhea, constipation, and decreased appetite; no grade 4+ TEAEs among most frequent; TEAEs leading to treatment discontinuation occurred in 1/23 patients who received monotherapy and 1/17 patients who received combination therapy; In summary, the observations of multiple responses among such heavily pre-treated patients, including those with AXL TmPS of only 1%, support further evaluation of BA3011 in a Phase 3 registrational study

08:05 EST Heart Test Laboratories receives FDA confirmation for 510k clearance pathway - Heart Test Laboratories announced that it has received confirmation from the FDA to change the clearance pathway for its MyoVista wavECG device and associated AI-ECG algorithm to a more standard 510(k) submission from the more complex De Novo process. Andrew Simpson, Chief Executive Officer of HeartSciences, said, "The new FDA product classification for AI-ECG paves the way for a more structured and faster 510(k) process for our MyoVista device, as well as our industry leading library of AI-ECG algorithms. We also intend to deliver these algorithms using a cloud-based, hardware agnostic platform that will provide innovative AI-ECG diagnosis from millions of existing ECG devices around the world, in addition to our MyoVista device." Mr. Simpson added, "The switch to 510(k) will require some changes, but we believe it will result in faster clearance overall. In November, the core lab finished their work on our MyoVista pivotal study following the conclusion of patient recruitment announced earlier in 2023. We remain on track for submission of the MyoVista to the FDA in the first half of 2024 and a targeted clearance during 2024."

08:05 EST Ford, Xcel Energy collaborate on deployment of 30,000 EV charging ports - Ford Pro (F), the commercial division within Ford and Xcel Energy (XEL), announced a unique collaboration to support the deployment of 30,000 electric vehicle, or EV, charging ports in Xcel Energy service territories across the U.S. by 2030 with most upfront costs offset by Xcel for qualifying business fleet customers. Ford Pro and Xcel Energy are launching the 30x30 initiative within Xcel Energy's broader Electric Vehicle Supply Infrastructure program to scale EV adoption and increase access to charging infrastructure for business fleets across Xcel Energy's service areas in the U.S. Through the program, most upfront costs for EV charging equipment and installation for businesses will be offset by Xcel Energy. Ford Pro will offer its suite of end-to-end charging solutions to Xcel Energy business customers as part of the effort. Starting in 2024, 30x30 will be available through Xcel Energy's EVSI program in Colorado and Wisconsin. The program will seek opportunities for expansion in future states over the next six years within Xcel Energy's service territories, pending regulatory approvals, including Michigan, Minnesota, New Mexico, North Dakota, South Dakota and Texas.

08:03 EST Curis signs agreement for emavusertib/pembrolizumab combination melanoma study - Curis (CRIS) has entered into an investigator-initiated clinical trial agreement with the University of Florida to study the combination of emavusertib and pembrolizumab in patients with metastatic melanoma. Curis is responsible for supply of emavusertib, Merck (MRK) is responsible for supply of pembrolizumab and clinical study costs. Both companies retain 100% of the commercial rights to their respective programs. The study is expected to begin enrollment in first half 2024.

08:01 EST BorgWarner CFO Kevin Nowlan to retire, Craig Aaron to succeed - BorgWarner announced that Kevin Nowlan has decided to retire as Executive Vice President and CFO after a 28-year career in finance. Craig Aaron, BorgWarner's current Vice President and Controller, will succeed Nowlan as Executive Vice President and CFO, effective March 1, 2024. Nowlan will remain with the company in an advisory capacity through April 1, 2024, to ensure a smooth transition. Aaron joined BorgWarner in 2007 and has held a number of positions in accounting and finance, including Controller, Treasurer, and Vice President of Finance for BorgWarner Morse Systems. Prior to joining BorgWarner, he worked at Federal-Mogul Corporation as a Corporate Account Manager and at Deloitte & Touche LLP as an In-Charge Auditor.

07:46 EST Saia to acquire 17 Yellow Corp. terminals in Chapter 11 sale for $235.7M - Saia, Inc. (SAIA) is the winning bidder for 17 terminals of Yellow Corporation (YELL) auctioned in connection with Yellow's pending Chapter 11 bankruptcy. Saia has agreed to pay a total of $235.7M for Yellow terminals located in the following markets: Fresno, California; Seaford, Delaware; Augusta, Georgia; Bowling Green, Kentucky; Paducah, Kentucky; West Boston, Massachusetts; Grand Rapids, Michigan; Grayling, Michigan; Duluth, Minnesota; Owatonna, Minnesota; Trenton, New Jersey; Rochester, New York; Akron, Ohio; Youngstown, Ohio; Reading, Pennsylvania; Knoxville, Tennessee; and Laredo, Texas. The closing of the transaction is expected in the first quarter of 2024 and is subject to various conditions, including approval by the U.S. Bankruptcy Court for the District of Delaware of the sale and regulatory approvals. A hearing to seek court approval is expected on December 12, 2023. Saia intends to pay the purchase price with a combination of cash on hand and availability under its credit facilities.

07:42 EST Tradeweb Markets reports November average daily volume $1.80T, up 59% YoY - Tradeweb Markets reported total trading volume for November 2023 of $38.2T. Average daily volume, ADV, for the month was a record $1.80T, an increase of 59.2 % year-over-year YoY . In November 2023, Tradeweb records included: ADV in U.S. government bonds and ADV in European government bonds and ADV in swaps/swaptions = 1-...Fully electronic U.S. credit ADV was up 32.0% YoY to $6.1bn and European credit ADV was up 29.7% YoY to $2.3B. Strong U.S. credit volumes, most notably record ADV in fully electronic U.S. High Grade activity, reflected continued client adoption in Tradeweb protocols, including request-for-quote , as well as record adoption in Tradeweb AllTrade(R) and portfolio trading. Tradeweb's share of fully electronic U.S. High Grade and U.S. High Yield TRACE was 16.7%, and 7.0%, respectively. Record European credit volumes were supported by strong activity in portfolio trading and Tradeweb Automated Intelligent Execution .

07:41 EST Ecarx partners with Black Sesame Technologies, BlackBerry - ECARX (ECX) announced that it has partnered with Black Sesame Technologies and BlackBerry Limited to jointly deploy its Skyland ADAS platform in Lynk & Co's flagship SUV, the Lynk & Co 08. ECARX Skyland Pro is powered by the BlackBerry QNX Neutrino Real-Time Operating System and Black Sesame Technologies' Huashan II A1000 ADAS computing chip. This robust tech stack supports the ECARX Skyland Pro with exceptional computing power, stability, reliability, and safety. This deployment not only marks the Company's inaugural mass-production of the ECARX Skyland Pro, but also represents the first large-scale production and application of the Black Sesame A1000 chip for use in ADAS solutions. Lily Cai, Senior Vice President, China Sales & Marketing of ECARX, said, "ECARX is committed to leading the way for the industry with its ADAS solutions. We are very excited to have completed the deployment and mass production of our first ADAS platform, the ECARX Skyland Pro. This is a significant breakthrough for ECARX in this critical technology field and is a testament to the unwavering support we have received from our industry-leading partners, Black Sesame Technologies and BlackBerry."

07:40 EST Cytomed Therapeutics signs research agreements in China and Taiwan - CytoMed Therapeutics has entered into a Heads of Agreement - HOA - with CytoMed Therapeutics China, a company incorporated in Hong Kong and a Memorandum of Understanding - MOU - with BioNex Solutions. The HOA forms a collaborative effort between CytoMed and CytoMed China to explore and investigate the safety, tolerability, potency, and efficacy of CytoMed's proprietary allogeneic gamma delta T cells for the treatment of various cancers - including solid tumors - in human subjects through an investigator-initiated trial in the People's Republic of China. The IIT is to be initiated through an entity to be incorporated in Chongqing, a municipality directly under the Central Government. CytoMed will provide technical assistance in the planning and conduct of the clinical trial and will grant CytoMed China, a loan of up to an aggregate of S$1M over three years. CytoMed is granted a first right of refusal to acquire a majority interest in CytoMed China, a new set-up by independent third parties. CytoMed has recently entered a MOU with BioNex Solutions, a company incorporated/headquartered in Taiwan, Republic of China, to explore the potential application of CytoMed's unmodified allogeneic gamma delta T cells in patients who have no authorized therapy options for their relevant medical conditions. BioNex is a private company with patient-centric care facilities, targeting unmet medical needs in cancer treatment.

07:40 EST PickleJar to deploy authID's identity life-cycle platform - PickleJar Entertainment Group announced that the company will deploy authID's identity life-cycle platform, combining PickleJar's industry leading artists payments, social commerce, performance ticketing and crowdfunding services with authID's world class enterprise delivery and next-gen fraud mitigation technology services. The PickleJar-authID partnership brings together deep skills in payments and security strategy, product ideation, technology development and deployment, and data analytics to make it frictionless to make, manage, and move money between artists, venues, and fans.

07:39 EST Poet Technologies announces goals for 2024 - POET Technologies issued a letter to shareholders from its CEO, Dr. Suresh Venkatesan, providing a review of recent accomplishments and vision for 2024. The letter read in part, "POET is committed to our strategic vision of commercializing our advanced device integration technology, which we believe enables us to solve multiple design, performance and scaling challenges in optoelectronic products and to fill an emerging void in solutions that address bandwidth and latency issues in artificial intelligence networks. Through 2023, we have managed to expand our product portfolio, boost POET's mindshare among leading companies in the market and position ourselves for rapid growth as we introduce leading-edge products to the market in 2024. Despite those accomplishments, it has been a challenging year, at least in part because of a difficult global capital market environment for pre-revenue microcap companies. While our recent equity financing fell short of our expectations, resulting in the need to raise additional capital in the relatively near future, we continue to discuss financing alternatives with investors and with partners who share our vision and exhibit confidence in the value of our technology and our technical achievements. Multiple potential avenues to financing remain, and we will continue exploring each of them in parallel over the next few months....Goals for 2024: In 2020, POET established Super Photonics Xiamen, a joint venture with San'an Integrated Circuits, a subsidiary of the giant San'an Optoelectronics Co. Ltd. SPX has since established a world-class assembly and test facility for optical engines without any contribution of capital from POET. The decision to fund the optical engine manufacturing through a joint venture structure required tradeoffs. It gave SPX the right to market and sell 100G, 200G and 400G optical engines to module customers, the large majority of which are based in China. It meant that POET would have to give up the early revenue associated with these sales, which are now set to flow into SPX beginning in 2024. As we were cutting our teeth on a brand-new technology and a first-of-its-kind integration platform, the Company needed to develop and support products that were of interest to smaller suppliers and/or for niche applications. During much of 2022 and 2023, the primary benefit to POET of this arrangement was to demonstrate the cost, performance, reliability and scalability of the POET Optical Interposer and the engines on which they are based and to bridge the chasm between development and manufacturing thereby establishing the viability of the interposer architecture. Over the past several months that has changed, as POET has introduced leading-edge, high-speed engines for 800G and established a roadmap through 3.2T. This has enabled access and penetration to a substantially larger and growing market fueled by the insatiable demands of AI. As POET's technological advantages become apparent within the industry, we also recognize the need to design, build and sell our own modules targeted for AI, not only to improve time to market but also to establish our own brand in a market that is expected to grow at an almost exponential rate. The "semiconductorization of photonics" process that is our hallmark provides advantages of cost, scale and power, which should allow us to compete effectively against incumbent solutions. Our goals for 2024 include: Completing a transmit optical engine design that will incorporate EMLs, which have become an industry standard at 400G and 800G, operating at both 100G per lane and 200G per lane; Incorporating those engines into an 800G 2xFR4 POET module; Completing a receiver design that operates at 200G per lane with an integrated TIA; Initiating production of an 8-channel packaged light source for AI applications; Gaining sufficient financing for the Company to complete these developments and to continue operations well into 2025 and beyond. With advanced optical engines that can be produced at scale attracting the attention of leading companies in the industry, we are determined to improve shareholder value through our continued commercialization efforts."

07:37 EST ICE awarded $155M for PennyMac misuse of Black Knight confidential information - Intercontinental Exchange announced that an arbitrator has found PennyMac Loan Services engaged in unauthorized use of Black Knight's confidential information in building the PennyMac Servicing Systems Environment SSE . The arbitrator awarded more than $155M, plus interest and attorneys' fees to Black Knight based on PennyMac's conduct. PennyMac is a former client of Black Knight, and ICE completed its acquisition of Black Knight in September 2023.The arbitrator determined that in developing its SSE software, PennyMac incorporated confidential information from Black Knight's MSP system and breached its contract with Black Knight with respect to such confidential information. ICE will continue to seek the robust protections afforded to trade secrets and confidential information under federal and state law, including in products developed using its confidential information.

07:36 EST Daktronics announces priorities for 2024 - CEO Reece Kurtenbach added, "As we look ahead, we expect growth in the global use of sophisticated audio-visual communication systems in both traditional and in new applications. Our attention remains focused on our multi-year journey to capture the market's expected growth and broaden our leading market position by offering best in class technology, capabilities and services to both our traditional customer base as well as new and adjacent markets." Looking forward, our focus is to: Grow our business profitably while generating cash through working capital management, strategic pricing adjustments, product mix enhancements and careful expense management; Improve operational efficiency to lower costs, reduce lead times and improve the customer experience; Develop additional markets for new customers and channels while continuing to grow in the markets where the company been a leader to date; Implement robust integrated business planning systems to generate data-based insights for improved decision making; Investing in high-return projects and technologies, including digital technologies for both internal and customer facing uses; Monitor and then adjust as necessary to the ever-evolving geopolitical and global economic environment to maintain profitability and cash generation

07:36 EST J.M. Smucker sees annual cost synergies of approximately $100M - The company stated in prepared remarks, "We expect long-term annual net sales growth for the Sweet Baked Snacks business of approximately 4%. We anticipate expanded distribution for both Hostess and Smucker products through the complementary capabilities of the combined businesses supporting our long-term growth expectations. We also anticipate annual cost synergies of approximately $100 million, half of which are expected to be realized in fiscal year 2025, with the full annualized amount to be achieved by the end of fiscal year 2026. We anticipate the Sweet Baked Snacks business to be accretive to adjusted earnings per share next fiscal year, as a result of a full-year of ownership, business growth, synergy realization, and interest expense reduction through debt paydown."

07:34 EST Annovis Bio announces last patient last visit in Phase III study of buntanetap - Annovis Bio announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson's disease. Topline data results are expected in January 2024. "We are pleased to share the completion of our Parkinson's study which marks a significant step forward in our ongoing mission to bring new therapies for those affected by this challenging neurodegenerative disease," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "The study saw a substantial level of participation, with patients enrolling at a record pace."

07:33 EST ZW Data Action Technologies announces partnership with Digital Life - ZW Data Action Technologies announced its strategic partnership with Digital Life Technology, pursuant to which the parities will work together on developing a specialized AI model tailored for the franchise industry. The goal is to amplify digital marketing capabilities by leveraging AI-driven methodologies. The collaboration's cornerstone is the integration and analysis of diverse key data types to build a custom AI model designed for the franchise sector. By combining ZW Data's extensive data expertise and resources in the franchise industry with Digital Life's AI technologies, the partnership aims to develop a transformative tool. "Our partnership aims to introduce groundbreaking AI marketing tools to the franchise industry, improving marketing efficiency and providing clients with more personalized and precise marketing experiences. We view the integration of AI model in the franchise industry as a technological breakthrough and a key step in driving the digital transformation of the franchise industry. The collaboration between ZW Data and Digital Life opens new market opportunities, propelling the digital transformation of the franchise sector and energizing the growth of SMEs," commented Handong Cheng, Chairman and Chief Executive Officer of ZW Data.

07:24 EST Hansa Biopharma announces restructuring with 20%-25% workforce reduction - Hansa Biopharma plans to restructure the organisation to better align and focus on key clinical development and commercial priorities. The planned restructuring would result in an approximately 20-25% reduction in the current workforce and will result in approximately SEK75-85M in annual savings when implemented. The restructuring is subject to negotiation with relevant trade unions. As part of the restructuring, Hansa will notify the Swedish Public Employment Service and seek consultations with the trade unions regarding the reorganisation. Decisions regarding employee reductions will take place after the change consultations have been concluded according to local regulations.

07:14 EST Pilot Travel, GM, EVgo open first 17 locations of fast charging network - Pilot Travel Centers, General Motors (GM) and EVgo (EVGO) announced the opening of the first 17 locations of their previously announced national electric vehicle fast charging network. Now available in 13 states, the network features an elevated charging experience. Pilot Travel Centers, GM, and EVgo, along with multiple public agencies and utilities, have worked together to grow the nation's public fast charging infrastructure, creating a model for how public-private collaboration can make measurable progress in accelerating broader access to EV charging. The three companies have worked to provide current and future EV drivers with an accessible charging experience for long distance travel. EV travelers will be able to find available charging locations via GM's vehicle brand apps, Pilot's myRewards Plus app, the EVgo app, PlugShare and other applications designed for EV drivers. By the end of 2023, it is expected that at least 25 Pilot and Flying J travel centers will feature EV fast charging, with approximately 200 locations targeted by the end of 2024. In total, the network will include up to 2,000 high-power fast charging stalls at up to 500 Pilot and Flying J travel centers across the U.S.

07:11 EST Enthusiast Gaming, Campbell's Chunky partner for FuelUp Tournament - Campbell's Chunky and Enthusiast Gaming Holdings are partnering to level up the soup brand's gaming strategy with a sponsorship of the popular video gaming series, NFL Tuesday Night Gaming. The comprehensive sponsorship program will be part of the second season of NFL TNG, a collaboration between the National Football League and Enthusiast Gaming, featuring NFL players and Legends teaming up with top gaming creators to compete in popular video games. NFL TNG season two premiered September 12, 2023, on NFL TNG's Twitch, YouTube and X channels. As part of the campaign activation, Enthusiast Gaming has launched the Chunky FuelUp Community on Discord, connecting gamers with Fortnite developers, streamers and NFL talent in building and playing a brand-new Fortnite Creative game mode in the Chunky FuelUp Plaza. Throughout the campaign, the Discord channel will serve as a hub for community members to participate in live Community Game Nights with participating Fortnite creators SypherPK and Symfuhny and NFL players Ray-Ray McCloud and James Daniels. The immersive activation will culminate in a live tournament featuring the top scoring gamers, Fortnite streamers and NFL talent at the NFL TNG All-Star Game on January 30.

07:09 EST G-III Apparel appoints Dana Perlman as Chief Growth and Operations Officer - G-III Apparel Group announced the appointment of Dana Perlman as Chief Growth and Operations Officer, effective January 8. In this newly created role, Ms. Perlman will draw on her over 20-year career in apparel, strategy and finance to drive innovation, optimize operations and identify new opportunities for G-III. As part of the company's leadership team, she will oversee Strategy, Finance, Communications, Information Technology, and other Operating functions. Most recently, Ms. Perlman spent over 10 years at PVH Corp. where she played a critical role in transforming the business as Chief Strategy Officer, having led global business strategy and development, along with Treasury and Communications, including Investor Relations.

07:07 EST Evogene signs distribution Agreement with WinField United Canada for Yalos - Evogene's Lavie Bio subsidiary announced a distribution agreement exclusive to independent retail with WinField United Canada for its bio-inoculant seed treatment Yalos. This partnership aims to support Lavie Bio's 2024 sales growth strategy in Canada, with a focus on key agricultural regions. Lavie Bio's intent is to engage with additional complimentary distribution partners to expand its sales reach throughout North America.

07:07 EST DavidsTea expands tea footpring in Canadian wholesale market - DAVIDsTEA announced a series of go-to-market initiatives to expand its footprint among Canadian wholesalers. DAVIDsTEA continues to increase its presence in the Canadian market by adding new storefronts, expanding its store-in-store concept and launching new products within existing accounts. The Company recently introduced six tea sachet flavors at 220 Staples Canada stores, showcasing organic options such as David's Breakfast Blend, Cream of Earl Grey, Silk Dragon Jasmine, and herbal, caffeine-free blends Cold 911 and Cinnamon Rooibos Chai. The assortment also features a popular coffee replacement black tea, Vanilla Cappuccino. Additionally, DAVIDsTEA has brought eight popular tea flavors to 47 Farm Boy grocery stores in Ontario. In Quebec, DAVIDsTEA entered the Jean Coutu and Brunet pharmacy accounts through the release of "12 Holiday Teas" and "12 Winter Classics" tea discovery gifts. These seasonal products will be available at select pharmacies during the holiday season with potential expansion of the offering in the coming months. DAVIDsTEA also launched its best-selling Matcha Variety Packs at over 800 Shoppers Drug Mart/Pharmaprix locations and introduced four additional flavours, including Matcha varieties, at Sobeys stores across Canada. Finally, DAVIDsTEA increased its store-in-store count by expanding within 40 Neighbourly Pharmacy locations last month. The Company will also be adding 15 store-in-store concepts within the Rexall Pharmacy Group in December to raise its total of similar configurations to 382 locations in Canada.

07:06 EST J.M. Smucker cuts FY24 free cash flow view to $530M from $650M - Raises FY24 CapEx view to $610M from $550M.

07:04 EST TELA Bio to take part in 'Connecting the Dots' - TELA Bio took part in a segment in Connecting the Dots, a series of branded films presented by MedTech Europe and including a film produced for them by BBC StoryWorks Commercial Productions. The Connecting the Dots series will include a mini-documentary style film, A Perfect Match, produced for TELA Bio highlighting the use of OviTex Reinforced Tissue Matrix in hernia repair. Annually, surgeons perform an estimated 20 million hernia repair procedures worldwide. Most of these surgeries involve the use of a mesh implant to strengthen the repair and minimize the risk of recurrence. While a range of hernia reinforcement options exists, including permanent plastic and tissue-derived materials, many prospective patients may not be aware of the newer alternatives available for their hernia surgery.

07:02 EST Science 37 announces 1-for-20 reverse stock split - Science 37 Holdings will effect a 1-for-20 reverse stock split of its outstanding common stock, par value $0.0001 per share, that will become effective on December 8, 2023, at 12:01 a.m., Eastern Time. Science 37's Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SNCE" and will begin trading on a split-adjusted basis when the market opens on December 8, 2023. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 808644207. The Reverse Stock Split is part of the Company's plan to regain compliance with the $1.00 minimum bid price requirement for maintaining its listing on Nasdaq. There is no guarantee the Company will meet the minimum bid price requirement. At the Company's Special Meeting of Stockholders held on November 29, 2023, the Company's stockholders approved a proposal to authorize a reverse stock split of the Company's Common Stock, at a ratio within the range of 1-for-5 to 1-for-30. The Company's board of directors approved a 1-for-20 reverse split ratio, and on December 4, 2023, the Company filed a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation to effect the Reverse Stock Split effective December 8, 2023.

06:58 EST Spire Global awarded space services contract by Lacuna Space for six satellites - Spire Global was awarded a Space Services contract by Lacuna Space, a satellite IoT connectivity provider. Under the agreement, Spire will initially build and launch six satellites carrying Lacuna Space's payload and antenna, with the opportunity to scale the constellation to dozens of satellites. Lacuna Space will operate its payloads and receive encrypted data at its Harwell headquarters.

06:57 EST AutoZone reports inventory up 3% y/y - The company's inventory increased 3.0% over the same period last year driven by new store growth. Net inventory, defined as merchandise inventories less accounts payable, on a per store basis, was negative $197,000 versus negative $249,000 last year and negative $201,000 last quarter.

06:53 EST The Buckle announces $2.50 per share special cash dividend - The Buckle authorized a $2.50 per share special cash dividend to be paid to shareholders of record at the close of business on January 12, 2024. The Board also authorized a 35c per share quarterly dividend to be paid to shareholders of record at the close of business on January 12, 2024. Both the $2.50 per share special cash dividend and the 35c per share quarterly dividend are payable on January 26, 2024 and will be paid together.

06:51 EST Stantec announces 2024-2026 strategic plan - Stantec released the highlights of its 2024-2026 Strategic Plan, including its three-year financial targets and guidance for 2024. By the end of 2026, Stantec aims to achieve: net revenue of $7.5B, organic net revenue growth at a three-year compound annual growth rate of greater than 7%; adjusted EBITDA margin in the range of 17%-18%: adjusted diluted EPS at a CAGR of 15%-18%. Stantec has identified key global trends and drivers that are re-shaping the world and has focused its go-forward plans on three broad strategic growth initiatives: Climate Solutions, Communities and Infrastructure of the Future, and Future Technology. These initiatives form the foundation of Stantec's organic growth plans for the next three years.

06:43 EST CVS Health increases quarterly dividend 10% to 66.5c per share - CVS Health has announced that its board of directors has approved a quarterly dividend of 66.5c per share, an approximate 10% increase from sixty and a half cents 60.5c per share. The dividend is payable on February 1, 2024, to holders of record on January 22, 2023.

06:38 EST Ares Management raises about $3.3B of real estate secondaries capital - Ares Management announced that it has raised approximately $3.3B of real estate secondaries capital, which comprises the Landmark Real Estate Fund IX, General Partner commitments and affiliated vehicles.

06:34 EST XPO, Inc provides North American LTL operating data for November 2023 - XPO reported certain preliminary LTL segment operating metrics for November 2023. LTL tonnage per day decreased 0.4%, vs. November 2022, attributable to a year-over-year increase of 3.8% in shipments per day and a decrease of 4.1% in weight per shipment. CEO Mario Harik said, "We're continuing to make good progress on a number of fronts in Q4 despite the soft freight market. November was our eighth consecutive month of year-over-year growth in shipments per day at a 3.8% increase. And our yield ex-fuel growth is tracking ahead of expectations for the quarter, with continued strength heading into 2024. There's a strong correlation between these operating gains and our strategy to become the industry's best service provider. By enhancing our service quality, we're increasing our yield and can capture more profitable share when industry tonnage rebounds. Through the first two months of this quarter, we continued to improve our damage frequency to a new company record."

06:32 EST Teleflex awarded peripheral access agreement with Premier - Teleflex (TFX) announced it was awarded the Peripheral Access purchasing agreement with Premier (PINC). Effective December 1st, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex's Peripheral Access products. Premier has awarded Teleflex a national multi-source agreement for Peripherally Inserted Central Catheters, PICC navigation equipment, and Midlines.

06:07 EST RadNet launches pilot MammogramNow offering inside Walmart - RadNet (RDNT) announces MammogramNow, a screening mammography service set to debut at the Walmart (WMT) Supercenter in Milford, Delaware, on December 8th. This initiative aims to enhance breast health awareness and accessibility, including the integration of DeepHealth technology, into the Walmart Supercenter environment, providing women with access to breast cancer screening services. By placing the MammogramNow program within the Walmart Supercenter, RadNet and Walmart seek to make breast health screenings more accessible, encouraging proactive, community-based healthcare. As part of the pilot, RadNet will actively promote breast health education and awareness initiatives.

06:04 EST Enovis president and COO Brady Shirley to retire at end of 1Q25 - Enovis Corporation announced that Brady R. Shirley, the company's President and COO, has informed the company's Board of Directors of his plans to retire at the end of Q1 2025. Brady will step down from his current position as President and COO on April 1, 2024, and assume the role of Executive Advisor, continuing to focus on the successful integration of the pending Lima acquisition, innovation, and mentorship of Enovis business leaders. Shirley's transition to retirement at the end of the first quarter 2025 will be managed with ample time for overlap with other relevant executives within the organization, the company said in a statement. He will remain a member of the company's Board of Directors.

06:02 EST Guild Holdings names Adam O'Daniel SVP and CMO - Guild Mortgage appointed Adam O'Daniel as Senior Vice President and Chief Marketing Officer. In this newly created role, O'Daniel will spearhead the company's marketing and communications initiatives. O'Daniel served in leadership roles for Open Mortgage and Movement Mortgage. Before joining the mortgage industry on the corporate side, O'Daniel contributed to the industry as a journalist, working as a financial editor and business reporter for more than a decade. O'Daniel joins Guild from Open Mortgage where he was the senior vice president of marketing and was responsible for branding, marketing, and communications for the residential mortgage lender. Previously, he served in marketing and communications leadership at Movement Mortgage.

05:58 EST Siemens, Intel to collaborate on advanced semiconductor manufacturing - Siemens (SIEGY) and Intel (INTC) announced Monday that they have signed a memorandum of understanding to collaborate on driving digitalization and sustainability of microelectronics manufacturing. The companies will focus on advancing future manufacturing efforts, evolving factory operations and cybersecurity, and supporting a resilient global industry ecosystem. "Semiconductors are the lifeblood of our modern economies. Few things run without chips. Therefore, we're proud to collaborate with Intel to quickly advance semiconductor production. Siemens will bring its entire cutting-edge portfolio of IoT-enabled hardware and software and electrical equipment to this collaboration," said Cedrik Neike, CEO of Digital Industries and member of the Managing Board of Siemens AG. "Our joint efforts will contribute to achieving global sustainability goals." The MoU identifies key areas of collaboration to explore a variety of initiatives, including optimizing energy management and addressing carbon footprints across the value chain.

05:14 EST Genentech announces INAVO120 study met primary endpoint - Genentech, a member of Roche, announced results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The study met its primary endpoint of progression-free survival, demonstrating a statistically significant and clinically meaningful improvement compared to palbociclib and fulvestrant alone. Overall survival data were immature at this time, but a clear positive trend has been observed. Follow-up will continue to the next analysis. The inavolisib combination was well tolerated and adverse events were consistent with the known safety profiles of the individual study treatments, with no new safety signals observed.

05:07 EST RLX Technology acquires two e-vapor companies for $25M - RLX Technology announced that it entered into two share purchase agreements with two target companies and their respective shareholders with a total consideration of approximately $25M. The entry of the share purchase agreements for business acquisitions and the transactions contemplated thereunder have been approved by the company's board of directors and audit committee. Each of the two target companies are in the e-vapor industry in its home country, located in Southeast Asia and North Asia, respectively. The transactions contemplated under the share purchase agreements for business acquisitions are expected to facilitate the company's international expansion in Southeast Asia and North Asia. The company also plans to continue its overseas expansion in the future